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ABSTRACT 
Dementia and mild cognitive impairment (MCI) are often caused by progressive 
and irreversible pathologic brain changes. Alzheimer’s disease, cerebrovascular disease, 
and Lewy body-related diseases are the most common causes with many individuals 
having mixed etiologies. Characterizing risk factors for dementia and MCI is complex 
due to overlapping etiologies, long latency periods, and the influence of cognitive 
reserve. While major risk factors including advanced age, hypertension, and the ApoE4 
allele have been identified, further investigation of early- and mid-life risk factors is 
needed. Using data from the Atherosclerosis Risk in Communities (ARIC) 
Neurocognitive Study, we examined prospectively risk factors for dementia and MCI.  
In the first manuscript, we assessed the association between life course 
socioeconomic status (LC-SES) and dementia and MCI. Low individual-level LC-SES 
was associated with an increased risk of dementia. Low individual-level economic factors 
of LC-SES (e.g. income, home ownership) were associated with increased risk of 
dementia independent of educational attainment. However, neighborhood-level LC-SES 
was not associated with risk of dementia or MCI. 
The second manuscript assessed the association between thyroid dysfunction 
(measured via autoimmune thyroid disease (AITD) and thyroid hormone levels) and risk 
of dementia and MCI. We found no association between AITD and dementia and MCI. 
Subclinical hypothyroidism was associated with a lower risk of dementia while overt 
hyperthyroidism, particularly with very elevated serum FT4 hormone levels, was 
associated with an increased risk of dementia compared to euthyroid participants.  
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The third manuscript examined the association between lifetime history of 
migraine symptoms and risk of dementia and MCI. Despite published evidence of brain 
abnormalities in migraineurs, which might lead to cognitive impairment, we found no 
association between migraine and dementia and MCI. 
This dissertation extends our understanding of risk factors for cognitive 
impairment underscoring the importance of early- and mid-life exposures on late-life risk 
of dementia and MCI.  
  
v 
 
TABLE OF CONTENTS 
LIST OF TABLES ......................................................................................................... viii 
LIST OF FIGURES ......................................................................................................... xi 
CHAPTER 1. PATHOPHYSIOLOGY OF DEMENTIA AND MILD COGNITIVE 
IMPAIRMENT (MCI)...................................................................................................... 1 
1.1. Introduction ............................................................................................................ 1 
1.2. Natural History of Alzheimer’s Disease and Related Dementias ...................... 2 
Alzheimer’s Disease (AD) ........................................................................................... 2 
Cerebrovascular Disease (CeVD) ............................................................................... 4 
Parkinson’s Disease (PD) and Lewy Body Disease (LB disease) ............................... 6 
1.3. Cognitive Reserve ................................................................................................... 8 
Education ..................................................................................................................... 9 
Socioeconomic Status (SES) ...................................................................................... 10 
1.4. Diagnosis and Treatment ..................................................................................... 10 
CHAPTER 2. EPIDEMIOLOGY AND PUBLIC HEALTH IMPACT OF 
COGNITIVE IMPAIRMENT ....................................................................................... 12 
2.1. Incidence and Prevalence .................................................................................... 12 
2.2. Disparities ............................................................................................................. 13 
Racial Disparities ...................................................................................................... 14 
Sex Disparities ........................................................................................................... 15 
Geographic Disparities ............................................................................................. 16 
Birth Cohort Disparities ............................................................................................ 17 
2.3. Economic Burden ................................................................................................. 18 
CHAPTER 3. RISK FACTORS .................................................................................... 20 
3.1. Introduction .......................................................................................................... 20 
3.2. Demographic ......................................................................................................... 20 
Age ............................................................................................................................. 20 
Sex .............................................................................................................................. 21 
Race and Ethnicity ..................................................................................................... 22 
3.3. Genetic ................................................................................................................... 23 
vi 
 
Alzheimer’s Disease and Apolipoprotein E (ApoE) .................................................. 24 
Lewy Body-related Diseases ...................................................................................... 27 
Cerebrovascular Disease .......................................................................................... 28 
3.4. Vascular................................................................................................................. 29 
Hypertension .............................................................................................................. 29 
Obesity ....................................................................................................................... 31 
Diabetes Mellitus ....................................................................................................... 31 
Hypercholesteremia ................................................................................................... 33 
3.5. Behavioral ............................................................................................................. 34 
Cigarette Smoking ..................................................................................................... 34 
Alcohol Consumption ................................................................................................ 36 
Diet ............................................................................................................................ 37 
Physical Activity ........................................................................................................ 39 
3.6. Summary ............................................................................................................... 40 
CHAPTER 4. STUDY DESIGN: ATHEROSCLEROSIS RISK IN COMMUNITIES 
(ARIC) STUDY COHORT ............................................................................................ 43 
4.1. Overview ............................................................................................................... 43 
4.2. Study Design and Population .............................................................................. 43 
4.3. Neurocognitive Study (NCS) ............................................................................... 45 
Dementia and MCI Classifications and Adjudication ............................................... 49 
CHAPTER 5. MANUSCRIPT 1: LIFE COURSE SOCIOECONOMIC STATUS 
AND RISK OF DEMENTIA AND MCI ....................................................................... 52 
5.1. Overview ............................................................................................................... 52 
5.2. Background ........................................................................................................... 54 
5.3. Methods ................................................................................................................. 56 
Statistical Analysis ..................................................................................................... 60 
5.4. Results ................................................................................................................... 62 
5.5. Discussion .............................................................................................................. 64 
5.6. Tables and Figures ............................................................................................... 69 
vii 
 
CHAPTER 6. MANUSCRIPT 2: ASSOCIATION OF ABNORMAL THYROID 
FUNCTION WITH DEMENTIA AND MCI ............................................................... 74 
6.1. Overview ............................................................................................................... 74 
6.2. Background ........................................................................................................... 76 
Statistical Analysis ..................................................................................................... 82 
6.4. Results ................................................................................................................... 83 
6.5. Discussion .............................................................................................................. 85 
6.6. Tables and Figures ............................................................................................... 88 
CHAPTER 7. MANUSCRIPT 3: MIGRAINES AND RISK OF DEMENTIA AND 
MCI .................................................................................................................................. 94 
7.1 Overview ................................................................................................................ 94 
7.2. Background ........................................................................................................... 96 
7.3. Methods ............................................................................................................... 100 
Statistical Analysis ................................................................................................... 102 
7.4 Results .................................................................................................................. 103 
7.5. Discussion ............................................................................................................ 104 
7.6 Tables and Figures .............................................................................................. 107 
CHAPTER 8. CONCLUSIONS ................................................................................... 113 
REFERENCES .............................................................................................................. 116 
APPENDIX .................................................................................................................... 135 
Life Course SES (Chapter 5) .................................................................................... 135 
Thyroid Dysfunction (Chapter 6) ............................................................................ 142 
Migraine (Chapter 7) ................................................................................................ 150 
 
 
  
viii 
 
LIST OF TABLES 
Table 1. 1. Clinical and diagnostic features of Lewy Body disease dementia and 
Parkinson’s disease with dementia, adapted from Jellinger, 201833 ................................... 7 
 
Table 2. 1. Incidence rates (95% CI) and hazard ratios (95% CI) of dementia by race, 
2000-2013, adapted from Mayeda, 201679 ....................................................................... 14 
 
Table 3. 1.  Age-stratified incidence rates (95% CI) of dementia per 1000 person years in 
the United States, adapted from Jorm,1998115 .................................................................. 21 
Table 3. 2. Odds ratios (95% CI) of developing AD by ApoE allele and race, adapted 
from Farrer, 1997134 and prevalence (% ± standard deviation) by ApoE allele, adapted 
from Singh, 2006135 .......................................................................................................... 26 
Table 3. 3. Summary of risk factors for MCI and dementia and clinical trial evidence, 
direction of risk, and strength of association .................................................................... 41 
 
Table 4. 1. Summary of ARIC-NCS clinic exams and components from 1987-present229
........................................................................................................................................... 45 
Table 4. 2. Description of cognitive tests administered as part of ARIC-NCS, 1990-
2017229,231,232 ..................................................................................................................... 46 
Table 4. 3. Summary of dementia and MCI cases identified in ARIC, 1987-2016 ......... 50 
Table 4. 4. Summary of etiology of adjudicated dementia and MCI cases (Level 1) at 
ARIC Visit 5, 2011-13 ...................................................................................................... 51 
 
Table 5. 1. Examples of SES measures at different life epochs.236,237 ............................. 54 
Table 5. 2. Individual and neighborhood life course socioeconomic factors and scoring 
adapted from Carson AP, 2007254 ..................................................................................... 58 
Table 5. 3. Baseline characteristics stratified by race, ARIC, 1987-89 ........................... 69 
Table 5. 4. Hazard ratios (95% CI) of dementia per pooled standard deviation increment 
of cumulative individual LC-SES and cumulative individual LC-SES with education 
removed, ARIC 1987-2013 ............................................................................................... 71 
ix 
 
Table 5. 5. Hazard ratios (95% CI) of dementia per standard deviation† increment of 
cumulative neighborhood LC-SES, ARIC 1987-2013 ..................................................... 73 
 
Table 6. 1. Prevalence of thyroid dysfunction in those ages >12: NHANES III (1988-
1994).272 ............................................................................................................................ 77 
Table 6. 2. Baseline characteristics stratified by clinical categories of thyroid 
dysfunction, ARIC 1990-92 .............................................................................................. 88 
Table 6. 3. Hazard ratios (95% CI) of dementia by anti-TPO positivity status, ARIC 
1990-2017 ......................................................................................................................... 90 
Table 6. 4. Hazard ratios (95% CI) of dementia by clinical categories of thyroid 
dysfunction, ARIC 1990-2017 .......................................................................................... 91 
Table 6. 5. Hazard ratios (95% CI) of dementia by categorical distribution of thyroid 
hormone level, ARIC 1990-2017 ...................................................................................... 92 
 
Table 7. 1. Baseline participant characteristics stratified by migraine status, ARIC, 1993-
1995................................................................................................................................. 107 
Table 7. 2. Hazard ratios (95% CI) and relative risks (95% CI) of dementia and MCI in 
relation to baseline headache status, ARIC 1993-2017 .................................................. 109 
Table 7. 3. Relative risks (95% CI) of dementia and MCI at visits 5 and 6 by etiology in 
relation to baseline headache status, ARIC 1993-2017 .................................................. 111 
Table 7. 4. Hazard ratios (95% CI) and relative risks (95% CI) of dementia and MCI in 
relation to baseline headache status and sex, ARIC 1993-2017 ..................................... 112 
 
Table A. 1. Literature review of the association between socioeconomic status and 
cognitive impairment ...................................................................................................... 135 
Table A. 2. Relative risks (95% CI) of adjudicated dementia and MCI per pooled 
standard deviation increment in cumulative individual LC-SES and cumulative individual 
LC-SES with education removed, ARIC 1987-2013 ...................................................... 139 
Table A. 3. Relative risks (95% CI) of dementia and MCI per standard deviation† 
increment of cumulative neighborhood LC-SES, ARIC 1987-2013 .............................. 141 
x 
 
Table A. 4. Literature review of the association between thyroid function and cognitive 
impairment ...................................................................................................................... 142 
Table A. 5. Relative risks (95% CI) of adjudicated dementia and MCI by anti-TPO 
positivity status, ARIC 1990-2017 ................................................................................. 145 
Table A. 6. Relative risks (95% CI) of adjudicated dementia and MCI by anti-TPO 
positivity status and etiology, ARIC 1990-2013............................................................. 146 
Table A. 7. Relative risks (95% CI) of adjudicated dementia and MCI by clinical 
categories of thyroid dysfunction, ARIC 1990-2017 ...................................................... 147 
Table A. 8. Relative risks (95% CI) of adjudicated dementia and MCI by categorical 
distribution of thyroid hormone level, ARIC 1990-2017 (Aim 2) .................................. 148 
Table A. 9. Literature review of the association between migraine and cognitive 
impairment ...................................................................................................................... 150 
  
xi 
 
LIST OF FIGURES  
Figure 3. 1. Spectrum of influence by genes versus environment on various dementias, 
adapted from Paulson and Igo, 2011130 24 
 
Figure 4. 1. ARIC visits and follow-up calls from 1987-present, adapted from the ARIC 
website229 44 
 
Figure 5. 1. Incidence rates of dementia stratified by life epoch and race-specific 
individual SES tertiles (low, middle, and high), ARIC 1987-2013 70 
Figure 5. 2. Race-specific age, sex, and ApoE4 status adjusted hazard ratio (95% CI) of 
incident dementia in relation to cumulative individual LC-SES with and without 
education, ARIC 1987-2013 72 
 
Figure 6. 1. Age, sex race-center, ApoE4, income, education, and TSH adjusted hazard 
ratio (95% CI) of incident dementia in relation to serum FT4*, ARIC, 1990-2017 93 
 
Figure 7. 1. Incidence rates of dementia adjusted for age and stratified by baseline 
headache subtype and sex, ARIC, 1993-2017 108 
 
1 
 
CHAPTER 1. PATHOPHYSIOLOGY OF DEMENTIA AND MILD COGNITIVE 
IMPAIRMENT (MCI) 
1.1. Introduction 
Cognitive function is typically characterized by five domains: learning and 
memory, language, visuo-spatial, executive, and psychomotor.1,2  These domains roughly 
correspond to their cerebral location and are identified and assessed using a mental status 
exam or neuropsychological testing.1,2 Mild cognitive impairment (MCI) generally 
involves deficiency of one domain whereas dementia involves impairment in two or more 
domains.1,2 MCI is a symptomatic pre-dementia state of clinical importance because of 
the increased risk of progressing to dementia (a decline in cognitive ability severe enough 
to compromise daily functioning).1,3 MCI and dementia can lead to a loss of 
independence and functioning that puts incredible strain on individuals, their families, 
caretakers, and healthcare systems.4,5  
Neurocognitive decline reflects a continuum of changes in cognitive function that 
can range from normal aging to pathologic decline (a change in cognition that exceeds 
the decline expected due to aging alone) caused by neurocognitive disease.6,7 Risk of 
neurocognitive decline (normal and pathologic) increases with age, especially among 
those over age 65.6,8 Neurocognitive decline and disease leading to MCI and dementia 
have become an ever-increasing public health burden in the United States as life 
expectancies rise and the older adult population at risk grows. However, there are still 
gaps in the knowledge of these devastating outcomes. Using rigorous epidemiologic 
methods to identify risk factors for MCI and dementia is important for identifying areas 
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to target for prevention of neurocognitive decline and disease to stop irreversible 
cognitive changes.6 
1.2. Natural History of Alzheimer’s Disease and Related Dementias 
Pathological changes to the brain in those with MCI and dementia are 
heterogeneous and caused by a variety of conditions.9 Etiology of neurocognitive disease 
is often identified as part of testing for MCI and dementia. For a definitive diagnosis, a 
brain autopsy or biopsy is necessary; however, brain imaging and assessment of 
symptoms are sufficient for diagnosis in many cases.10 The etiologic diagnoses for the 
majority of dementia and MCI cases include Alzheimer’s disease (44-70%) or 
cerebrovascular disease (15-37%), with other causes such as Lewy body disease and 
Parkinson’s disease (PD) being less common (5-17%).10-12 Approximately 56% of 
individuals with dementia and MCI have mixed etiology with mixed AD-cerebrovascular 
disease etiologies being the most common.10,11 
Alzheimer’s Disease (AD) 
 Alzheimer’s disease (AD) is a neurodegenerative disease with histopathological 
features of amyloid plaques containing β-amyloid protein (Aβ) and aggregation of tau 
protein in neurofibrillary tangles.12,13 These abnormalities are primarily found in the 
hippocampus, temporal cortex, and nucleus basalis of Meynert in the brain.12-14 
Formation of plaques containing Aβ is thought to be central to the pathogenesis of 
AD.15,16 Aβ is derived from the cleavage of amyloid precursor protein (APP) by a 
complex group of enzymes that include presenilin 1 (PS1 related to the PSEN1 gene) and 
presenilin 2 (PS2 related to the PSEN2 gene).15 While the neuronal function of APP is 
unknown, Aβ is a normal product of APP metabolism.15 Mutations in genes associated 
3 
 
with early-onset AD (including APP, PSEN1, and PSEN2 genes) are all associated with 
an over production of Aβ supporting the integral role of amyloid plaques with Aβ in the 
pathogenesis of disease.15 
 Tau is a microtubule-associated-protein (MAP) found in the axons of mature 
neurons and whose function is to promote the assembly of tubulin into microtubules and 
stabilize their structure.17,18 Under the right pathological conditions, tau binding to 
microtubules is disrupted leading to an increase in the levels of unbound tau and hyper-
phosphorylation of tau.17,18 Unbound tau is more likely to become misfolded creating 
early deposits called “pre-tangles.”17 A structural transition occurs leading to aggregation 
that is more organized and the development of hyper-phosphorylated neurofibrillary 
tangles.17,18 While the mechanisms of tau aggregation are not fully understood, levels of 
total-tau (T-tau) and phosphorylated tau (P-tau) are increased in the brains of individuals 
with AD making it an important component of the disease.15  
 While Aβ and tau are neuropathological and neurochemical hallmarks of AD, a 
number of cognitive, metabolic, structural, and molecular abnormalities have been 
observed years, even decades, before symptom onset.15 Levels of Aβ42 in cerebral spinal 
fluid (CSF) and Aβ deposition seen in brain imaging are above normal levels 20 years 
before symptom onset, followed by elevated tau levels measured in CSF 15 years before 
onset.15 Structural changes associated with synaptic loss such as hippocampal atrophy are 
seen 10 years before onset and cognitive changes measured by Clinical Dementia Rating-
Sum of Boxes (CDR-SB) as well as impaired glucose metabolism subsequently occur 
about 5 years before symptom onset.15 
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Clinically, AD starts as a progressive decline in cognitive function. Early on, this 
cognitive impairment predominantly affects complex daily living activities and causes 
short-term memory loss.19,20 Often, individuals mistakenly attribute these deficits to 
normal aging or stress and may not seek care or meet the diagnostic criteria for AD for 
several years.15,19,20 Episodic memory, the ability to consciously remember a particular 
episode in one’s life, and semantic memory, the ability to store conceptual and factual 
knowledge not related to a specific memory, are memory domains most severely 
impacted by AD.21 As the disease progresses, memory deficits worsen and may be 
accompanied by behavioral and psychological symptoms including emotional 
disturbances like depression, anxiety, apathy, and elated mood, delusions, disturbances in 
motor function, changes to circadian rhythm, and changes in appetite and eating.22 In the 
severest stages of disease, patients can no longer care for themselves, are unable to 
communicate verbally, and are often bed ridden. After AD diagnosis, the mean survival is 
5.9 years (standard deviation ± 3.7 years), with the most common immediate causes of 
death including cardiovascular disease (CVD), respiratory or blood infections, and 
cancer.23,24   
Cerebrovascular Disease (CeVD) 
 Cerebrovascular disease (CeVD) is characterized by a spectrum of conditions that 
involve cognitive impairment and evidence of stroke (cerebrovascular accident – CVA) 
or vascular brain injury.12 Vascular dementia (VaD) is a term that refers to individuals 
who develop dementia due to a vascular lesion, regardless of the pathogenesis.25 Vascular 
cognitive impairment (VCI) has been proposed as a term that better describes the range in 
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cognitive deficits related to cerebrovascular disease with VaD being the most severe 
manifestation.25  
 CeVD is caused by a heterogeneous group of conditions that can be divided into 
ischemic (80%) and hemorrhagic (20%) events.26,27  Hemorrhagic strokes are caused by 
spontaneous hemorrhage associated with hypertension, congenital and other atrial 
aneurysms, and arteriovenous malformations.28 Hypertension is the major risk factors for 
hemorrhagic stroke.26,28 Ischemic events are often associated with atherosclerosis and 
embolic disease and fall into three major categories, atherothrombotic occlusion, embolic 
occlusion, and small vessel occlusion.26,28 Atherosclerosis causes narrowing of blood 
vessels (with significant hemodynamic changes at 70% or more occlusion) due to 
atherosclerotic plaques and can lead to erosion of the endothelium.28 Embolic disease is 
generally caused by cardiac abnormalities such as atrial fibrillation or valvular disease 
that lead to occlusion with clot material or atheromatous (macrophage cells, lipids, 
calcium, etc.).28  Transient ischemic attacks (TIAs) are brief, reversible events caused by 
temporary occlusion of a vessel.26 Ten to 40% of patients who experience a TIA will go 
on to develop an ischemic stroke.26 Risk factors for ischemic events include age, 
hypertension, diabetes, and history of ischemic heart disease.26,28 
 From neuroimaging, damage caused by CeVD can be identified including 
evidence of large infarcts, lacunar infarcts, and white matter lesions (WMLs).29,30 Large 
infarcts are associated with VaD and can be caused by a single large vessel infarct that 
causes extensive damage or multiple large vessel infarcts.29 These infarcts are more likely 
to be found in the left hemisphere of the brain, but can be bilateral.29 Cognitive 
impairment usually becomes evident within three months of the large infarction and 
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persist indefinitely.29 Lacunar (small) infarcts are caused by small vessel occlusions or 
partial vessel occlusion in the deep cerebral white matter, basal ganglia, or pons, and 1-2 
are commonly found via neuroimaging in older adults without cognitive impairment.29,31 
More than two lacunes are usually necessary for VCI diagnosis and often occur 
concurrently with WMLs.29 WMLs are usually found in periventricular regions and can 
extend deep into white matter.29 To cause VCI, WMLs must be extensive and confluent.29 
A combination of risk factors, vascular disease, and brain damage are the hallmarks of 
CeVD and VCI.30 
Parkinson’s Disease (PD) and Lewy Body Disease (LB disease) 
 Parkinson’s disease (PD) and Lewy body disease can also impair cognition. Lewy 
bodies (LBs) are aggregated protein deposits of insoluble α-synuclein that can be found 
in the cortical and subcortical regions of the brain in LB-related dementias which include 
PD and LB disease.12 However, LBs are not strongly correlated with severity of LB-
related dementia.32,33 The abundance of Lewy neurites (LNs) and neuritic degeneration in 
the hippocampus and periamygdaloid cortex are strongly associated with cognitive 
impairment by disruption of the limbic loop (controlling emotion, memory, and 
motivation).33,34 While PD and LB disease share neuritic pathology based on abnormal 
aggregation of LBs, they are considered separate disorders despite debate about how to 
characterize their relationship.32 
  PD is characterized by movement disorder at least 1 year prior to cognitive 
decline, while LB disease is characterized by cognitive impairment up to 2 years prior or 
in conjunction with movement disorder.12,33 There are three core features of LB-related 
disease: 1) fluctuating cognition with variations in attention and alertness, 2) recurrent 
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visual hallucinations, and 3) spontaneous features of Parkinsonism.32,33,35 If only one core 
feature is present, there are three suggestive features including: 1) REM sleep behavior 
disorder, 2) neuroleptic sensitivity, and 3) low dopamine transporter uptake in the basal 
ganglia evident in neuroimaging.33 Unlike AD and CeVD, cognitive impairment is not 
necessarily the primary early clinical feature of PD or LB disease.35 Many clinical 
features of PD and LB disease overlap making the temporal relationship between 
cognitive impairment and movement disorder (Parkinsonism) the differentiating factor 
(Table 1.1).32,33,35 
Table 1. 1. Clinical and diagnostic features of Lewy Body disease dementia and 
Parkinson’s disease with dementia, adapted from Jellinger, 201833 
Major Clinical 
Features 
Lewy Body Dementia Parkinson’s Disease Dementia 
Chronology Dementia precedes by ≤ 2 years prior to onset of Parkinsonism 
Parkinsonism precedes 
dementia by ≥ 1 year 
Cognitive 
impairment 
Deficits in attention, executive 
function, and visuospatial 
ability 
Impairment of more than one 
memory domain (executive 
function, episodic memory, 
etc.) 
Memory impairment less 
prominent at onset, but 
increasing (fast rate of decline) 
 
Fluctuating 
cognition 
Marked variation in alertness 
and attention 
If present, similar to LB 
disease 
Hallucinations Recurrent, most often visual 
Particularly present after drug 
therapy (Levodopa) and in 
some drug naïve patients 
Motor 
Parkinsonism 
Usually absent before dementia 
occurs, tremor rare or absent 
Variable akinesia, rigidity, 
tremor frequent 
REM sleep 
behavior disorder 
(RBD) 
May precede onset for many 
years or develop after onset Similar to LB disease 
Associated non-
motor clinical 
features 
Daytime sleepiness, episodes of 
unresponsiveness, neuroleptic 
sensitivity, orthostatic 
Mood and personality 
changes similar to LB disease 
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hypotension, urine 
incontinence, constipation, 
falls, syncopes, hyposmia, 
depression, apathy, anxiety 
with neuroleptic sensitivity 
less frequent 
 
1.3. Cognitive Reserve  
 Cognitive reserve is based on the observation that brain pathology and damage are 
not directly related to cognitive function.36,37 Cognitive reserve is considered an effect 
modifier on the relationship between brain pathology and clinical outcomes (MCI and 
dementia). Mature adults with higher cognitive abilities are hypothesized to tolerate more 
brain pathology before cognition is noticeably impacted compared to those with lower 
cognitive abilities.36,37 Neuroimaging and autopsy studies for AD, CeVD, PD, and LB 
disease have found that those with high measures of cognitive reserve had higher levels 
of cognitive function with more pathological evidence of disease compared to those with 
lower measures of cognitive reserve.38-42   
 There are several hypotheses used to explain cognitive reserve and describe how 
it develops. One of the more widely accepted theories includes concepts of passive and 
active reserve. Passive reserve, also referred to as brain reserve, describes brain structures 
(such as size and neuronal count) that make the brain more efficient as evidenced by 
enhanced memory retrieval and problem solving.36-38 Active reserve, also referred to as 
cognitive reserve, is defined as neuronal compensation, which allows the brain to utilize 
alternate networks to compensate for pathology.36-38 Education, complex occupation, and 
sustained intellectual engagement are thought to be factors in determining levels of active 
reserve.36-38  
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 There is no standard measure of cognitive reserve despite its important to our 
understanding of the development of MCI and dementia. Measures of active reserve, 
including education and socioeconomic status (SES), are widely used proxies, because of 
their association with environmental exposures related to cognitive advantage.36 
Education 
 Education is the most commonly used surrogate measure of cognitive reserve.38,43 
The hypothesized relationship between education and dementia through cognitive reserve 
theory is supported by autopsy studies that have found no association between brain 
pathology at autopsy and years of education; this suggests that while education may not 
protect against developing neurocognitive disease, among those who do develop disease, 
their risk of MCI and dementia is lower.44,45 However, education as a surrogate measure 
for cognitive reserve remains complicated and our understanding is incomplete. 
 How education is measured reflects the cultural context of the population being 
studied. Studies in developing regions may include participants with no education, 
whereas in developed nations, even the lowest categories of educational attainment 
include some years of education. A meta-analysis of papers examining education and 
dementia found that the association between education and dementia did not depend on 
categorical cut points for educational attainment.43 The relationship between education 
and dementia is more complex than increased education linearly reducing risk of 
dementia. To address this complexity, some researchers have opted to use SES (which 
includes measures of education) as a proxy for cognitive reserve.46,47 
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Socioeconomic Status (SES) 
 SES, also referred to as socioeconomic position (SEP), is defined as “social and 
economic factors that influence which positions individuals or groups will hold within the 
structure of a society.”48 Education, wealth, income, occupation, and housing 
characteristics (renter/owner) are common measures of SES and can be assessed at the 
individual- and neighborhood/area- level. In measuring SES, there are three main 
components: education, employment, and money.49 In particular, education is an integral 
part of SES because higher levels of education are generally associated with greater 
upward mobility, leading to higher levels of other SES factors (more wealth, higher 
income, complex occupation, more likely to own home, etc.) as well as social and 
behavioral advantages.49,50  
 The connection between SES and health has long been established with some 
researchers describing SES as a ‘fundamental’ determinant of health.49 Low SES, 
specifically, has been identified as a risk factor for many chronic diseases including 
diabetes, cancer, CVD, and dementia.51-55 Further, the relationship between low SES on 
risk factors and health behaviors on chronic disease risk are seen as early as childhood 
and adolescence.56 Contributions of SES to cognitive reserve are not fully understood, but 
these sociodemographic factors represent a complex accumulation of lifetime exposures 
that must be considered with examining MCI and dementia outcomes later in life.    
1.4. Diagnosis and Treatment 
 Diagnosis of MCI and dementia involves neuropsychological testing, assessment 
of medical, neurological, and psychiatric history, a medical exam, neurological and 
psychiatric exam, laboratory tests, and brain imaging, usually with magnetic resonance 
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imaging (MRI).57 The most common tests used for the neuropsychological testing are the 
Mini Mental State Exam (MMSE) and the Clock Drawing Test (CDT).58  Cognitive tests 
are meant to be quick and easy, have an acceptable positive likelihood ratio (diagnostic 
accuracy), and be repeatable over time to track cognitive change.57,58 Medical, 
neurological, and psychiatric history, a medical exam, and laboratory tests, are used to 
distinguish between pathologic decline and normal aging as well as identify potentially 
reversible causes of cognitive impairment including depression, side effects of 
medication, thyroid dysfunction, and B12/folate deficiency.59 Finally, neuroimaging is 
used to help determine etiology of disease; though, as mentioned previously, definitive 
etiologic diagnosis for MCI and dementia can only be determined after death with a brain 
autopsy or biopsy.59 
 Identifying disease etiology in patients with MCI and dementia is important for 
predicting the course of disease and deciding on secondary and tertiary prevention 
strategies. For AD, PD, and LB disease, there are no effective treatments to stop or 
reverse cognitive decline, only tertiary prevention interventions that may temporarily 
slow disease progression as well as treatments to help with symptoms, particularly related 
to behavior and mood.60,61 For CeVD, cognitive impairment caused by CeVD events 
cannot be reversed with treatment, however, there are effective secondary and tertiary 
prevention interventions.62,63 Common treatments include antihypertensive medications, 
statins for hyperlipidemia, antiplatelet therapy such as aspirin, carotid endarterectomy, 
smoking cessation, and anticoagulant therapy such as warfarin.62  
Overall, there are no effective treatments for MCI and dementia, and development 
of treatments is complicated by the major overlap in brain pathologies.64 
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CHAPTER 2. EPIDEMIOLOGY AND PUBLIC HEALTH IMPACT OF 
COGNITIVE IMPAIRMENT 
2.1. Incidence and Prevalence  
 MCI has an estimated prevalence of 16-20% in those ages 50 and older and 
increases markedly with age.59,65 MCI is associated with an increased risk of incident 
dementia and total mortality.59,65 Of those with MCI, 12-20% will progress to dementia 
annually, 40-70% will not progress to dementia even after 10 years, and 15-20% will 
experience improved cognition within 2 years (though this group remains at elevated risk 
for future cognitive decline).59 The incidence of MCI ranges widely from 5.1 to 168.0 
cases per 1000 person years among those ages 50 and older.65 Of note, the term MCI does 
not have a standard definition, so incidence and prevalence estimates can fluctuate 
substantially between studies depending on the diagnostic criteria for MCI that was 
used.66  
 An estimated 5.3 million Americans are living with dementia and 5.1 million of 
those are over the age of 65.67 The prevalence of dementia is estimated to be 13% in 
those ages 65 and older and increases exponentially with age, doubling every 5 years 
after age 65.67-69 The incidence of dementia is estimated to be approximately 33.3 cases 
per 1000 person years in those 65 and older.69-71 As with prevalence, incidence of 
dementia increases with age, though, by ages 85-90, the rise in incidence rate begins to 
decelerate and may even plateau.69  
 In addition, there are important differences in the epidemiology of MCI and 
dementia sub-types. AD has a prevalence of 10-30% and a mean annual incidence of 10-
30 cases per 1000 people among those ages 65 and older.15 The prevalence of CeVD is 
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3% in the U.S. adult population; however, 11% of those between ages 55-64 have 
asymptomatic cerebral ischemic abnormalities on neuroimaging, rising to 43% among 
those ages 85 and older.72 The incidence of stroke doubles each decade after age 55 with 
those 65-74 having an annual incidence of 6.7-9.7 incident strokes per 1000 people.72 PD 
has an estimated prevalence of 1-5% and older and an annual incidence of 0.13 cases per 
1000 people among those ages 65 older.73,74 The estimated prevalence of LB disease 
among those 50 years and older is 0.4% with an annual incidence of 0.04 cases per 1000 
person years.75,76 Overall, AD is by far the most common cause of MCI and dementia 
among older adults followed by CeVD, PD, and LB disease. 
2.2. Disparities  
 There are notable variations in the prevalence and incidence of MCI and dementia 
among subpopulations in the United States that will likely have major public health 
implications as demographics of the country shift over time. The U.S. population is 
getting older and more diverse, which, with no other change, will lead to an increased 
number of individuals at elevated risk of dementia as well as a heightened need for 
culturally appropriate dementia assessment and management tools.77 By 2030, 20% of the 
population is projected to be 65 or older, a 6% increase from 2012.78 The racial diversity 
of the older adult population is also increasing with the proportion of non-Hispanic 
whites projected to decrease by 18% (from 79% to 61%) by 2050.77,78 Racial disparities 
have become an important area of research in MCI and dementia because of these 
expected changes to the population. Additionally, there are geographic, sex, and birth 
cohort disparities in neurocognitive disease that should be considered. 
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Racial Disparities 
 There is increasing interest and research in identifying and characterizing racial 
disparities in dementia due the projected population trends. A 2010 report estimated that 
African Americans and Hispanics had 2 and 1.5 times the risk of all-type dementia, 
respectively, compared to non-Hispanic whites.67 Valid comparison of incidence and 
prevalence of MCI and dementia across race groups is challenging because few studies 
have been able to use standardized diagnostic criteria to assess MCI and dementia within 
a diverse, multi-racial population.67 A recent study of inequalities in dementia incidence 
attempted to address this problem using data from older adults (≥ 65 years old) receiving 
medical care through Kaiser Permanente Northern California.79 African Americans had 
the highest incidence and hazard of dementia followed by American Indians/Alaskan 
Natives, Latinos, Pacific Islanders, and whites with Asian Americans as the references 
group (Table 2.1).79  Further, there are many bi-racial studies, most often comparing 
African Americans and whites or Hispanics and whites, which have shown racial 
disparities in MCI and dementia.80-83 
 
Table 2. 1. Incidence rates (95% CI) and hazard ratios (95% CI) of dementia by race, 
2000-2013, adapted from Mayeda, 201679 
Race/Ethnicity 
Age-adjusted Incidence Rate 
per 1000 person years 
(95% CI) 
Hazard Ratio 
(95% CI) 
African American 26.60 (25.83, 27.37) 
1.65 
(1.58, 1.72) 
American 
Indian/Alaskan Native 
22.18 
(20.85, 23.52) 
1.32 
(1.24, 1.41) 
Latino 19.59 1.24 
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(18.97, 20.20) (1.19, 1.29) 
Pacific Islander 19.63 (14.51, 24.75) 
1.23 
(0.95, 1.58) 
White 19.35 (19.16, 19.54) 
1.22 
(1.18, 1.26) 
Asian American 15.24 (14.73, 15.74) 
1.00 
(ref) 
 
 Despite evidence suggesting prevalence and incidence of dementia varies between 
ethno-racial groups, there is no consensus on racial disparities in MCI and dementia for 
several reasons.84 There is concern that cognitive tests used to identify cognitive decline 
and dementia may lack convergent validity between race groups, cultural biases may 
interfere with self-report and informant-report of cognitive function, and socioeconomic 
differences (such as education and income) often, in part, the result of racism, make 
comparison between race groups challenging.80,84 Further, there may be delays in 
diagnosis and treatment for cognitively impaired individuals from minority populations 
leading to more severe symptoms at diagnosis.80,84  These cultural factors likely influence 
the disparities in MCI and dementia that have been observed, but further research is 
needed to determine the extent of these biases.   
Sex Disparities 
 Sex disparities have been observed in MCI and dementia, but their cause is 
believed to vary by subtype. AD prevalence is significantly higher in women than men, 
with almost two-thirds of individuals living with AD in the U.S. being women.85 
However, studies of incident disease show that risk of AD is not significantly higher in 
women compared to men, suggesting the difference in prevalence is explained by the fact 
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that women live longer on average.85,86 Based on the current literature, there is no sex 
disparity in AD, only sex differences in life expectancy and thus lifetime at risk of AD.85  
 CeVD and stroke incidence is higher in men than women until age 85 after which 
women have a higher incidence.87 Incident stroke in women occurs, on average, 5 years 
later than men, women have a greater lifetime risk due to a longer life expectancy, and 
women are more likely to experience stroke related disability and cognitive impairment, 
possibly due experiencing stroke at an older age when pre-stroke independence and 
abilities were already compromised.88-90 The delayed onset of CeVD has been 
hypothesized to be caused by cardio protective estrogen; however, this view has been 
disputed in clinical trials.91 Sex differences in CeVD are likely caused by a combination 
of longer life expectancy in women, modifiable vascular risk factors, and genetics.91     
 Unlike AD and CeVD, sex disparities in dementia with LBs (including PD and 
LB disease) have not been extensively studied and are not well established, likely due to 
the relative rarity of these diseases. Evidence from autopsy indicates men have a higher 
prevalence of dementia with LBs compared to women.92 This sex disparity is especially 
evident among those with pure LB pathology compared to those with mixed pathologies 
(LB disease + AD).92 Researchers have hypothesized that the disparity is related to a 
neuro-protective role of estrogen, but is likely related to a complex mix of biological and 
environmental factors.92-94  
Geographic Disparities 
In addition to possible racial and sex disparities, there are geographic disparities 
in MCI and dementia across the United States. The “Stroke Belt” is a well-established 
phenomenon where stroke morbidity and mortality is highest in the 8-state region of the 
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Southeastern part of the country.95,96 Vascular risk factors are believed to explain half of 
the disparity, but there remains regional drivers that are not fully understood.95 The 
geographic pattern of stroke incidence and mortality as well as the overlap between 
vascular risk factors, cerebrovascular disease, and dementia, have prompted further 
investigation of the relationship between geography and dementia incidence and 
mortality. Studies have shown that not only do individuals who spent their early years in 
the “Stroke Belt” have an elevated risk of stroke later in life regardless of where they 
reside, but also that states with high stroke mortality tend to have elevated Alzheimer’s 
disease mortality.97-99 Going further, individuals born in the “Stroke Belt” have a greater 
risk of incident dementia as well as dementia mortality regardless of residence late in life 
or at death.100,101 The geographic disparity in dementia suggests that there are robust early 
life and childhood geographic risk factors for MCI and dementia that require further 
investigation. 
Birth Cohort Disparities 
 Epidemiologic study of older adult populations has shown that changes in 
educational attainment and improved modifiable vascular risk factors have led to reduced 
risk of MCI and dementia among younger birth cohorts compared to older cohorts. 
Glymour, et al., 2008 examined changes to compulsory schooling laws (mandatory 
enrollment age and years of compulsory schooling) in the United States as a natural 
experiment to understand the association between education and cognitive impairment 
between birth cohorts (birth year <1914, 1914-1921, 1922-1930, 1931-1941, and 1942-
1947).102 The study found that birth cohorts affected by changes in compulsory schooling 
laws had higher educational attainment and performed better on cognitive tests later in 
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life (≥ age 50) compared to earlier birth cohorts that completed school before the law 
changes.102 In addition, CVD mortality peaked in the United States in the late 1960s and 
has since declined, due, in part, to improved vascular risk factors and treatment including 
reduced smoking and the development of statins and antihypertensive medications.103 
Some studies have observed a decline in dementia incidence and prevalence between the 
1970s and 2010s and have attributed these changes to a combination of increased 
education and improved risk factors.104,105 However, these trends have not been 
consistent between study cohorts and require further longitudinal examination (especially 
in light of the rapidly aging population). 
2.3. Economic Burden 
 The cost of dementia care in the United States was estimated to be $215 billion in 
2010, and with the aging population and increased life expectancy, these costs are 
expected to more than double by 2040.106 While Medicare provides nearly universal 
healthcare for Americans over age 65, the population most at risk for MCI and dementia, 
Medicare does not cover all dementia-related expenses such as homecare services, 
homecare equipment, and non-rehabilitative nursing home care.107 Average out of pocket 
spending during the last five years of life for dementia patients was estimated to be 
$61,522 versus $28,818 for cancer patients and $35,294 for heart disease patients.107 The 
high costs associated with MCI and dementia primarily come from the formal and 
informal care patients need as the disease progresses and they lose their ability to carry 
out activities of daily living and instrumental activities of daily living.107  
 The majority of dementia patients (70-81%) live in the community and rely on 
caregivers to help with daily activities.108 Caregiving is considered “informal” work, and 
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caregivers are most likely to be a female family member of the MCI or dementia patient 
such as a spouse, sibling, or adult child.109,110 The estimated monetary value of caregiving 
in 2010 was $27,789 in addition to $13,188 in forgone wages.106 Caregiving is associated 
with a number of negative outcomes including family dysfunction, depression, financial 
stress, and reduced quality of life.110 Because patients with MCI and dementia often live 
for several years with increasing disability, the impact of neurocognitive disease on 
families and communities can be tremendous. Research into prevention and treatment of 
MCI and dementia is essential not only for those who will be at risk of disease, but also 
their families who will be deeply impacted.  
   
20 
 
CHAPTER 3. RISK FACTORS 
3.1. Introduction 
 MCI and dementia are caused by a complex mix of demographic, genetic, 
behavioral, and vascular risk factors. This chapter will describe these major risk factors 
for MCI and dementia as well as possible mechanisms by which they influence disease 
risk. Unless otherwise specified, estimates of dementia incidence and prevalence as well 
as the epidemiology of risk factors will refer to U.S. or European studies. While there are 
noted geographic disparities throughout the world, methodological issues and limited 
data prevent wider generalization.111 Socioeconomic status will be described in detail in 
Chapter 5 followed by novel risk factors of thyroid function and migraine described in 
Chapters 6 and 7, respectively.  
3.2. Demographic 
 Age 
 Age is the strongest risk factor for MCI and dementia, and among those ages 80 
and older, it is the only consistent statistically significant predictor of cognitive 
impairment.69 “Late-onset” is sometimes used to describe dementia (especially AD) that 
is diagnosed at or after age 65 while “early-onset” describes dementia diagnosed before 
age 65. Late-onset dementia is far more common than early-onset, though, cognitive and 
structural changes are measureable well before symptomatic onset of disease regardless 
of age at diagnosis.15 Between ages 65 and 90, the risk of dementia increases 
exponentially and almost doubles every 5 years (Table 3.1).67-69 However, few studies 
have examined dementia and MCI in those ages 90 and older. There is some debate 
whether MCI and dementia incidence continues to rise after age 90 and how 
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quickly.70,112,113 However, prevalence of dementia in this group is estimated to be 28-
44%.114 
 
Table 3. 1.  Age-stratified incidence rates (95% CI) of dementia per 1000 person years in 
the United States, adapted from Jorm,1998115 
Age Group, years 
Estimated Incidence 
per 1000 person years (95% CI) 
65-69 2.4 (1.9, 3.0) 
70-74 5.0 (4.3, 5.7) 
74-79 10.5 (9.4, 11.6) 
80-84 17.7 (16.1, 19.4) 
85-89 27.5 (23.7, 32.0) 
 
 Early-onset (also known as young-onset) dementia represents less than 10% of 
AD cases, has an incidence of 0.67-0.98 cases per 1000 people, and is most likely to 
occur between the ages 45 and 64.116,117 As with late-onset dementia, the most common 
etiologic causes are AD and CeVD, followed by frontotemporal dementia.116  Patients 
with early-onset MCI and dementia are more likely to be misdiagnosed compared to late-
onset cases, likely due to their age rather than differing manifestations of disease.116    
Sex 
 Female sex is strongly associated with risk for MCI and dementia as well as a 
source of disparities.118 As mentioned previously, higher risk of AD and CeVD in women 
is largely related to the longer life expectancy, while higher risk of dementia with LBs in 
men may be due neuroprotective estrogen.96,118 Contributing to the sex disparities evident 
in MCI and dementia are disparities in modifiable risk factors.  
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 Men are more likely to smoke, have CVD (specifically coronary artery disease), 
and experience a brain injury with loss of consciousness, while women are more likely to 
be obese, all factors that increase risk of MCI and dementia.118 In addition, there is 
mounting evidence that diabetes and hypertension disproportionately affect women’s risk 
of cognitive impairment compared to men’s risk despite similar prevalences.119 Coronary 
heart disease (CHD) is a major risk factor for MCI and dementia that is more prevalent in 
men; however, the female risk advantage is negated in women with diabetes.119-121 
Further, women with diabetes are estimated to have a 19% increased risk of MCI and 
dementia compared to men with diabetes.122 Prevalence of hypertension, a particularly 
important risk factor of stroke and CeVD, is higher in men compared to women in middle 
age, but as age increases, prevalence rises to 75% among women 75 years and older 
compared to only 65% among men of a similar age.123  
 Thus, sex alone may not be a risk factor for dementia, but men and women differ 
in risk factor prevalences, particularly age that must be addressed in research. Midlife 
vascular risk factors are associated with the development of later life MCI and dementia, 
and are modifiable in men and women.124  
Race and Ethnicity 
 As mentioned in Chapter 2, there are disparities in MCI and dementia incidence 
and prevalence by race; specifically, higher rates in African Americans, American 
Indians/Alaskan Natives, and Hispanics followed by whites, and lower rates in Asian 
Americans.79,125 However, there is no consensus on racial disparities due to convergent 
validity of cognitive tests, cultural biases that interfere with self and informant-report of 
cognitive function, and socioeconomic differences.80,84,125 Moreover, there are disparities 
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in modifiable vascular risk factors for MCI and dementia that may, in part, be driving 
potential racial disparities.   
 A meta-analysis found that African Americans and Hispanics had higher 
prevalence of hypertension, diabetes, obesity, hypercholesteremia, smoking, and physical 
inactivity compared to whites.126 In contrast, Asian Americans had a lower prevalence of 
hypertension, diabetes, smoking, obesity, and physical inactivity compared to whites.127 
These risk factor levels mirror the differences in incidence and prevalence of MCI and 
dementia by race. There is also a strong relationship between race and socioeconomic 
status (typically measured by income and education), as well as heterogeneity within 
racial and ethnic groups, that further complicate documenting the independent 
relationship between race and MCI and dementia.128,129 As with sex disparities, studies 
generally adjust for modifiable risk factors in addition to race and SES. However, the 
complexity of the relationship between SES, race, and cognitive impairment may require 
advanced statistical methods to fully adjust for potential confounders. 
3.3. Genetic 
 Genetic variations play an important role in the development of most age-related 
dementias. Neurodegenerative disease etiologies can be thought of as falling along a 
spectrum of genetic and environmental influence (Figure 3.1).130 As discussed in Chapter 
1, AD and LB-related dementias are caused by misfolding and aggregation of proteins, 
known as proteinopathy. Dementias caused by proteinopathy can be hereditary and 
caused by dominant-acting disease gene mutations or non-hereditary (also known as 
sporadic) and involve a number of genetic and environmental factors.130 The genetic 
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factors associated specifically with AD and LB-related disease most often play a role in 
the development of proteinopathy.130  
 
Figure 3. 1. Spectrum of influence by genes versus environment on various dementias, 
adapted from Paulson and Igo, 2011130  
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Alzheimer’s Disease and Apolipoprotein E (ApoE)  
 The majority of AD, especially late-onset cases, are sporadic, while early-onset 
AD is more likely to be hereditary.130 Early-onset familial AD is caused by autosomal-
dominant single-gene mutations on chromosomes 21, 14, and 1.117,130 Amyloid precursor 
protein gene (APP) found on chromosome 21 encodes amyloid precursor protein (APP), 
a neuronal membrane protein from which Aβ is released.117,130 Any one of 32 mutations 
in APP can cause the formation of abnormal APP from which Aβ is derived.130-132 This 
abnormality in APP leads to the over production of a less soluble, more toxic form of Aβ 
called Aβ42 (relative to Aβ40).130,132 One of 179 single gene mutations on the presenilin 1 
gene (PSEN1) on chromosome 14 or one of 14 mutations on the presenilin 2 gene 
(PSEN2) on chromosome 1 create proteins called presenilins (PS1 and PS2) that are 
important in the γ-secretase complex.130,132 The enzymes produced by PSEN1 and PSEN2 
are responsible for creating complex enzymes that cleave APP into Aβ.130,132 Mutations 
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in these enzymes result in the over production of Aβ42 relative to Aβ40, the same 
consequence of APP mutations.130,132 These gene mutations are responsible for less than 
2% of all AD cases and of them, PSEN1 mutations are the most common.132 
 In 50-70% of sporadic (late and some early-onset) AD cases, genetic factors play 
a significant role, though sporadic AD is not considered a genetic disorder.130,132 The 
most important genetic risk factor, contributing to approximately half of the genetic risk, 
is the apolipoprotein E (ApoE) gene found on chromosome 19.130,132 This gene is 
responsible for making a protein called apolipoprotein E, which combines lipids to form 
lipoproteins.133 Lipoproteins are responsible for packaging and carrying cholesterol and 
other fats through the bloodstream, which makes ApoE a significant factor in maintaining 
healthy cholesterol levels.131,133 Elevated cholesterol (hypercholesteremia) is associated 
with elevated risk of CVD and is strongly related to AD pathogenesis.131,133 ApoE 
mediates the delivery of cholesterol to the brain, an essential component for axonal 
growth, synaptic formation, and remolding.131 These events are vital to learning, memory, 
and neuronal repair.131 ApoE is also believed to influence Aβ metabolism by causing 
deposition of Aβ to form senile plaques and cause cerebral amyloid angiopathy, two 
hallmarks of amyloid pathology in AD brains.131 
 ApoE has three common polymorphic alleles, ε4 (ApoE4), ε3 (ApoE3), and ε2 
(ApoE2), which vary at two amino acids.130,132 ApoE4 is present in 10-20% of the 
American population and increases risk of AD, ApoE2 is the rarest allele and believed to 
have a protective effect, and ApoE3 is the most common allele and is believed to play a 
neutral role.132 The prevalence of ApoE alleles as well as the risk of AD varies by 
race/ethnic group (Table 3.2).134,135 An individual with two ApoE4 alleles will have the 
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highest risk of AD followed by those with one allele.117 Individuals with no ApoE4 
alleles have the lowest risk of AD.117 It is important to note that ApoE4 is a genetic risk 
factor, not a disease causing mutation, meaning that ApoE4 cannot cause AD nor does it 
need to be present for AD to develop, unlike the mutations in APP, PSEN1, and PSEN2 
implicated in familial early-onset AD.130 There is evidence of an ApoE gene-environment 
interaction with increased lifetime cognitive activity reducing the Aβ burden in the brains 
of ApoE4 carriers compared to ApoE4 carriers with less lifetime cognitive activity.136 
Genome-wide association studies have identified additional genetic risk factors for AD 
including CLU, PICALM, CR1, NIN1, ABCA7 MS4A cluster, CD2AP, CD33, and EPHA1 
genes, but none are as significant as ApoE with increased disease odds ratios of 1.1-1.2 
compared to 3.0-4.0 for ApoE4.130 
 
Table 3. 2. Odds ratios (95% CI) of developing AD by ApoE allele and race, adapted 
from Farrer, 1997134 and prevalence (% ± standard deviation) by ApoE allele, adapted 
from Singh, 2006135 
ApoE 
alleles Whites 
African 
Americans 
Hispanics 
 Japanese 
ApoE 
allele 
Prevalence 
in 
North 
America 
ε2/ε2 0.9 (0.3, 2.8) 
2.4 
(0.3, 22.7) 
2.6 
(0.2, 33.3) 
1.1 
(0.1, 17.2) 
ε2 0.05 ± 0.04 
ε2/ε3 0.6 (0.5, 0.9) 
0.6 
(0.4, 1.7) 
0.6 
(0.3, 1.3) 
0.9 
(0.4, 2.5) 
ε3/ε3 1 (Ref) 
1 
(Ref) 
1 
(Ref) 
1 
(Ref) 
ε3 0.82 ± 0.06 
ε2/ε4 1.2 (0.8, 2.0) 
1.8 
(0.4, 8.1) 
3.2 
(0.9, 11.6) 
2.4 
(0.4, 15.4) 
ε3/ε4 2.7 (2.2, 3.2) 
1.1 
(0.7, 1.8) 
2.2 
(1.3, 3.4) 
5.6 
(3.9, 8.0) ε4 0.13 ± 0.06 
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ε4/ε4 12.5 (8.8, 17.7) 
5.7 
(2.3, 14.1) 
2.2 
(0.7, 6.7) 
33.1 
(13.6, 80.5) 
 
Lewy Body-related Diseases   
 As with AD, LB-related diseases (LB disease and PD) are most often sporadic. 
However, research has identified a strong genetic component including several genes 
associated with the development of LB-related diseases. A mutation found in the α-
synuclein gene (SNCA) was the first evidence of a genetic basis for LB-related diseases, 
implicated in both PD and LB disease.137,138 Pathogenic mutations in SNCA are rare, but 
the gene is thought to cause α-synuclein aggregation, a pathogenic event in early LB 
dementias.137-139 Not all mutations in SNCA are fully penetrant, which is likely why there 
can be heterogeneity between members of the same family in terms of age at onset, 
phenotype, and pathology.138 Another gene identified in LB-related disease is LRRK2; 
1% of sporadic and 4-5% of familial PD is associated with the (relatively) common 
mutation p.G2019S, while rarer disease-associated variants are implicated in LB 
disease.137,139,140 The wide clinical-pathological variability associated with LRRK2 
suggests there are strong genetic modifiers yet to be identified.137 Finally, disease-
associated mutations in the GBA gene are the third major genetic factor commonly 
implicated in LB-related diseases.139 GBA mutations are believed to reduce the activity of 
the enzyme β-glucocerebrosidase leading to impaired degradation of α-synuclein and, 
thus, the aggregation commonly seen in LB-related disease.138 
 Of note, while PD and LB disease are related and share genetic risk factors (as do 
AD and LB disease), there is no known genetic overlap between PD and AD.138 PSEN1, 
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PSEN2, and APP mutations typically associated with AD are also believed to play a role 
in LB disease.138 The mechanism is not totally understood, however some researchers 
believe this association may be due to misdiagnosis of LB disease in AD patients or 
evidence of mixed AD-LB disease pathologies, both of which can only be confirmed with 
autopsy data.139 In addition, ApoE4 increases risk of both AD and LB disease and may be 
stronger risk factor for mixed AD-LB pathology than for AD pathology alone.139,141 
Cerebrovascular Disease 
 CeVD is caused by a combination of vascular, environmental, and genetic 
components. The genetic factors in CeVD are most often multifactorial and result from 
the interaction of many genes each with a relatively small affect.142 While monogenic 
diseases and susceptibility for CeVD are rare, some have been identified.142,143 Cerebral 
autosomal dominant ateriopathy with subcortical infarcts and leukoencephalopathy 
(CADASIL) is a rare, but well-characterized autosomal dominant small vessel disease 
that occurs in 2-4 per 100,000 adults. CADASIL is caused by a mutation in the NOTCH3 
gene that is known for causing infarcts and increasing risk of ischemic stroke with onset 
as early as the mid-20s through 30s.142,143 Additional rare CeVD-causing genetic 
mutations include, Fabry disease (an X-link recessive lysosomal storage disorder), 
mitochondrial encephalomyopathy lactic acidosis and stroke episodes (MELAS) (a 
disorder that is caused by mutations in mtDNA and known to cause stroke), and Myoma 
disease (MYMY) (a progressive, occlusive cerebrovascular ateriopathy).142 
 While monogenic diseases do not explain most CeVD related dementia, nor is 
CeVD considered a genetic disease, genetics of lipid disorders have been identified as 
potentially playing a role in the assessment of CeVD risk, especially ischemic stroke.142 
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A systematic review of 42 studies (n = 29,965) found that, compared to ApoE3, ApoE4 
was associated with increased prevalence of cerebral micro-bleeds, (especially in the 
lobar region of the brain), ApoE2 was associated with increased frequency of brain 
infarcts, and both ApoE4 and ApoE2 were associated with an increased risk of white 
matter hyperintensities.144 The underlying mechanism of ApoE’s association with CeVD 
is not fully understood, and it is unclear how ApoE variants influence lipid metabolism in 
the brain or whether they are related to neuro-inflammation, unlike AD where ApoE’s 
role is thought to be through Aβ metabolism.144 In addition to ApoE, familial 
hypercholesterolemia (FH), characterized by elevated blood cholesterol, tendinous 
xanthoma, and premature vascular disease (especially CHD), has been shown to increase 
risk of stroke in a Finnish study of more severe forms of FH, but few studies have looked 
at specific FH gene mutations (such as LDLR, ApoB, and PCSK9) and CeVD.  
 While there are clear genetic components to certain CeVDs, the relationship 
between genetics and cerebral events is not as strong as with other dementia etiologies. 
Further, pathophysiologic mechanisms are not well understood, in part, because of the 
blood brain barrier.145 There is limited understanding of the complex relationship 
between microvascular dysfunction and degeneration, neurovascular disintegration, 
defective blood brain barrier, and vascular risk factors.145 
3.4. Vascular 
Hypertension 
 Despite advancements in prevention and treatment of hypertension, it remains one 
of the most important risk factors for stroke and dementia (mainly through CeVD and AD 
etiology).146 The brain is particularly susceptible to damage caused by hypertension.146 
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Blood pressure is involved in the conduit and cushioning functions of the large arteries.147 
These functions are responsible for delivering blood throughout the body (conduit 
function) and transforming a pulsatile flow at the heart level to a steady-state flow at the 
peripheral level (cushioning function).147 As individuals age, large artery stiffening 
increases systolic blood pressure (SBP) and pulsatility, damaging microcirculation in the 
brain, heart, retina, and kidneys.148 The brain relies on adequate supply of oxygen and 
glucose, and microvascular damage caused by hypertension can cause profound 
alterations to the regulatory mechanisms that ensure this supply.146,149 This dysfunction is 
associated with lacunar infarcts, white matter damage, microinfarcts, and micro- and 
macro-bleeds, all hallmarks of CeVD and stroke.146,149 In clinical trials, a 10 mm Hg 
reduction in systolic blood pressure is associated with a 30% reduction in risk of stroke; 
this linear association continues down to a systolic blood pressure of 115 mm Hg and 
diastolic blood pressure of 75 mm Hg.150 Further, there is increasing evidence that 
hypertension-induced brain lesions associated with CeVD have a synergistic or additive 
effect on AD pathology.146 Nevertheless, a meta-analysis found that there was no 
consistent statistically significant association between AD and hypertension when 
measuring hypertension in mid- or late-life.151 
 Unlike CeVD and AD, data on hypertension and LB-related diseases is sparse. A 
meta-analysis of seven studies found that history of hypertension significantly increased 
risk of PD with a pooled relative risk of 1.80 (95% CI: 1.07, 3.04).152 However, three 
cohort studies used Taiwan National Health Insurance data and there was substantial 
publication bias.152 To our knowledge, no studies have assessed the association between 
LB disease and hypertension. 
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Obesity 
 The mechanisms by which obesity may increase risk of dementia are believed to 
be via the vascular and behavioral risk factors associated with obesity such as sedentary 
lifestyle, poor diet, hypertension, and obesity as well as white adipose tissue (WAT).153 
WAT is endocrine tissue that secretes cell-signaling molecules called adipokines, which 
refer to cytokines, acute phase reactants, growth factors, and other inflammatory 
mediators.153 There are hundreds of adipokines and the relationship between these 
molecules and dementia has been largely unexplored despite epidemiologic evidence 
supporting an association between adiposity and dementia.153  
 High midlife body mass index (BMI) defined as overweight (> 25-30 kg/m2) or 
obese (> 30 kg/m2) as well as high central adiposity (> 25cm) were each associated with 
double the risk of CeVD, AD, and total dementia in later life compared to those with a 
normal BMI (18.5-25 kg/m2) or normal central adiposity (< 25 cm).154-157 The 
relationship between obesity and PD or LB disease has not been studied as extensively, 
however, the evidence suggests there is a weak or no association with obesity.158,159 
Further, BMI over the life course generally follows a trajectory of increasing weight with 
age until reaching an inflection point between mid- and late life after which BMI 
decreases.153 This decrease later in life is associated with brain atrophy, white matter 
changes, and disturbances of the blood brain barrier suggesting midlife obesity may be 
more important for risk of cognitive decline compared to late-life obesity.153  
Diabetes Mellitus 
 Diabetes is an established risk factor for ischemic stroke and small vessel disease 
as well as associated with several vascular risk factors for dementia including obesity, 
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hypertension, and hypercholesteremia.160 There is a well-established relationship between 
type 1 and type 2 diabetes mellitus and modest changes in cognition.161 For type 1 
diabetes, this includes slowing of mental speed and reduced mental flexibility, and for 
type 2 diabetes, there may be changes in learning and memory, mental flexibility, and 
mental speed.162,163 A meta-analysis of 14 longitudinal studies found that diabetes was 
associated with almost double the risk of total dementia, AD, and CeVD.161 Few 
epidemiologic studies have assessed the relationship between diabetes and LB-related 
diseases, but a Finnish study found that risk of PD was almost two-fold higher in those 
with diabetes, compared to those without, mirroring study results for total dementia, AD, 
and CeVD.164 
 There are four main mechanisms by which diabetes is believed to be associated 
with cognitive impairment, chronic glucose toxicity, chronic hypoglycemia, impaired 
insulin sensitivity, and inflammation.160 Glucose toxicity is caused by hyperglycemia-
induced tissue damage, particularly in the retina, kidneys, and brain causing oxidative 
stress related to vascular damage and neurodegenerative brain disorders.160,165 
Hypoglycemia, particularly recurrent, severe episodes, can cause permanent neurologic 
damage and increase platelet aggregation and fibrinogen formation.160,166 Changes in 
insulin sensitivity can have profound effects on cerebral carbohydrate metabolism, due to 
the large concentrations of insulin receptors in the brain, and lead to energy deficits 
associated with neurodegenerative diseases.167 Finally, chronic inflammation, which is 
believed to be involved in type 2 diabetes, is also thought to play a role in cognitive 
impairment, though study of this relationship has been limited and relies on the measure 
of non-specific inflammatory biomarkers such as C-reactive protein and interleukin-6.160 
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Hypercholesteremia 
 The relation between blood levels of cholesterol and dementia is complicated by 
the blood brain barrier. While 23% of the body’s cholesterol is found in the central 
nervous system, all brain cholesterol is made locally and cut off from the blood supply of 
the rest of the body.168 Even so, cholesterol metabolism is believed to play an important 
role in neurodegenerative diseases, particularly with the discovery of ApoE4 as a genetic 
risk factor for AD.168 Cholesterol is known to influence the activity of enzymes involved 
in the metabolism of amyloid precursor protein and Aβ deposition.169 Animal and in-vitro 
studies have shown that increased dietary cholesterol accelerates Aβ deposition in the 
brain, though the mechanism is not fully understood.169 Further, cholesterol is also 
believed to play a role in tau production and production of neurofibrillary tangles.169 
Epidemiologic studies have found that hypercholesteremia in midlife increases the risk of 
late-life AD; though, no relationship has been found between late-life hypercholesteremia 
and risk of AD, suggesting the association may be age-dependent.170,171 
 In PD and LB disease, cholesterol oxidation has been hypothesized as a factor in 
α-synuclein aggregation, a pathological hallmark of LBs.168,172  Chronic inflammation is 
believed to cause cholesterol oxidation leading to α-synuclein overexpression.172 
However, the temporal relationship between the components in this proposed progression 
has not been established.172 A case-control study of brain samples from cases with LB-
related diseases (n=15) and controls without LB-related brain pathology (n=18) found 
that concentrations of oxidative cholesterol metabolites were significantly elevated in 
cases.172  
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 The relationship between blood cholesterol levels and cerebrovascular disease is 
equally complex with epidemiologic studies suggesting high total cholesterol is 
associated with ischemic stroke, while low total cholesterol is associated with 
hemorrhagic stroke.173 Hypercholesteremia is an important risk factor for coronary heart 
disease, and the strongest association between lipids and ischemic stroke is within the 
large artery atherothrombotic stoke subtype. However, there is no association between 
hypercholesteremia and embolic stroke.173 Low total cholesterol may play a role in 
hemorrhagic stroke due to the importance of cholesterol in the architecture and integrity 
of the endothelium of small vessels.173 Low cholesterol levels may impair endothelial 
repair causing “leakage” or obstruction of the vessels putting individuals at elevated risk 
of a hemorrhagic event.173 
3.5. Behavioral 
Cigarette Smoking 
 Cigarette smoking is the leading preventable cause of a number of chronic 
diseases including CVD, and prevalence in the United States is estimated to be 20%.174 
Smoking affects CVD risk via the pharmacological effects of nicotine including 
sympathetic stimulation and coronary vasoconstriction, inhaled carbon monoxide 
decreasing oxygen availability in the blood, smoke causing increased thrombotic factors 
including platelet activation, and inflammatory effects of toxic chemicals in cigarette 
smoke.174 These same mechanisms are the foundation of the relationship between 
cigarette smoking and CeVD events, including both ischemic and hemorrhagic stroke.175 
Current cigarette smokers have a 3-4-fold increased risk of stroke compared to never 
smokers, and those exposed to secondhand smoke have a 1.5-2-fold higher risk of stroke 
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compared to those not exposed to secondhand smoke.175 Further, smokers had a 1.38-fold 
(95% CI: 1.18, 1.45) higher risk of VaD compared to never smokers based on a meta-
analysis of five longitudinal studies.176 
 The relationship between other dementias (AD, and LB-related disease) and 
smoking is inconsistent and less well understood.176 A meta-analysis found that current 
smokers had 1.3-fold (95% CI: 1.2, 1.4) increased risk of all-cause dementia compared to 
never smokers, and that there was no statically significantly difference in dementia risk 
between former smokers and never smokers.176 However, the same meta-analysis found 
only a marginally significant association between current smoking and AD with a relative 
risk of 1.1 (95% CI: 1.0, 1.3).176 Further, a study of smoking and LB-pathology upon 
autopsy found no significant difference in LB pathology between those who had smoked 
0-5 pack years versus those who smoked >5-50 pack years, while participants who 
smoked >50 pack years had a relative risk of 0.4 (95% CI: 0.2, 0.9) compared to those 
who smoked >5-50 pack years.177  
 The inconsistent association between smoking and dementia, particularly AD and 
LB-related disease, is likely related to bias. Increased attrition seen in study participants 
that smoke as well as survival of some smokers given the known lethality of smoking, 
suggests that there may be beneficial characteristics (e.g. genetic risk factors, access to 
care, etc.) of smokers who survive long enough to be at risk for/develop dementia as well 
as chose to participate in epidemiologic studies.178,179 This selection bias pushes results 
towards (and sometimes beyond) the null.178 However, smoking is such a strong risk 
factor for disease (including CeVD and other dementia risk factors) that it is still an 
important behavioral risk factor for dementia and must be included in analysis. 
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Alcohol Consumption 
 Alcohol consumption at any age has an acute neurotoxic effect on the brain, 
which can lead to symptoms of cognitive impairment, blackout, and hangover that are 
reversible with alcohol withdrawal.180 Researchers believe the repeated neurotoxic effect 
of drinking, particularly heavy drinking and abuse, can cause alcohol-related brain 
damage/injury, a form of cognitive impairment that is clinically different from AD, VaD, 
and LB-related diseases and characterized by ventricular enlargement and diffuse atrophy 
primarily affecting the prefrontal regions.180,181 Alcohol-related brain damage/injury is 
often overlooked as a comorbid factor in dementia diagnosis.182 One review estimated 9-
22% of dementia patients abused alcohol and among alcohol abusers, 10-24% had 
dementia.182 However, the neuropathological link between alcohol-related brain 
damage/injury and dementia is not clear.182 Further, consumption patterns, type of 
alcohol, genetics, and a number of other clinical factors complicate the relationship and 
understanding of alcohol-related brain damage/injury.180,181,183 
 A meta-analysis of 15 longitudinal studies (n=14,646) found that light to 
moderate alcohol consumption was associated with a 25-28% reduction in risk of AD, 
VaD, and all-type dementia compared to non-drinkers, while risk of dementia in heavy 
drinkers versus non-drinkers did not significantly differ.184 Further, a case-control study 
found no association between risk of LB-related disease and alcohol consumption.185 
However, there are several caveats to these results. Heavy drinkers were less likely to live 
to old age, likely because heavy drinking is associated with elevated risk of 
cardiovascular disease, cancer, liver disease, and other chronic conditions that 
significantly increase mortality.184 The protective effect seen among light to moderate 
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drinkers may be a reflection of those individuals possessing other beneficial 
characteristics similar to what we see among smokers (e.g. genetics, access to care, etc.) 
as well as inadequate control for confounders.186  Emerging research using Mendelian 
randomization, pooled cohort studies, and multivariable adjusted meta-analysis has 
shown no protective effect of drinking on total mortality, cardiovascular disease, or AD, 
further suggesting the protective effect of alcohol on dementia may be due to bias.186-189   
Diet  
 The role of diet in prevention of chronic disease, particularly CVD, is primarily 
through maintaining a balanced, healthy food regimen and preventing vascular risk 
factors such as obesity, hypertension, and hypercholesteremia.190,191 The Mediterranean 
diet and Dietary Approaches to Stop Hypertension (DASH) diet have been studied and 
promoted as diets specifically for CVD prevention. The Mediterranean diet has been the 
most extensively studied and is associated with reduced risk of a number of chronic and 
age-related conditions including stroke, type 2 diabetes, CVD, and total mortality.191-196 
Traditionally, this diet is characterized by high intake of fruits, vegetables, cereals, and 
legumes, olive oil as the main source of fat, low consumption of red meat and processed 
meat, and moderate alcohol consumption (particularly wine).191 A meta-analysis of 11 
prospective cohort and cross-sectional studies and one randomized controlled trial 
showed that higher adherence to the Mediterranean diet was associated with reduced risk 
of AD and lower rates of cognitive decline.191  
The DASH diet was inspired by the Mediterranean diet and developed to prevent 
hypertension. This diet is characterized by an emphasis on consumption of fruits, 
vegetables, and low-fat dairy while restricting consumption of sodium, commercial 
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sweets, and saturated fat.197  A small clinical trial of 124 overweight (BMI: 25-40 kg/m2) 
men and women found that participants randomized to the DASH diet had better 
psychomotor speed after 4 months compared to usual diet controls.198 A cohort study 
from the Rush Memory and Aging Project found that increased adherence to the DASH 
diet was associated with significantly slower rate of cognitive decline on global cognitive 
test scores over an average follow-up of 4.1 years.199 
 While the Mediterranean and DASH diets have shown inverse associations with 
cognitive decline and dementia, neither were developed to increase the types of foods 
identified to be neuroprotective for dementia.197 Individual nutrients including vitamin E, 
B vitamins, folic acid, and n-3 fatty acids have been identified as potentially reducing risk 
of dementia.197  Observational and clinical studies have shown increased intake of n-3 
polyunsaturated fatty acids measured via food frequency questionnaires were associated 
with reduced risk of incident AD.200 Observational studies also supported increased 
consumption of vitamin E, B, and folic acid to reduce dementia risk, but results from 
intervention studies did not find a protective effect.200 Nevertheless, these nutrients have 
been identified as possible targets for a diet to prevent cognitive decline and dementia. 
The Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) 
diet was developed to address this gap by emphasizing plant-based foods, especially 
green leafy vegetables and berries, and limiting animal and high saturated fat foods.197 
Two cohort studies conducted in the Rush Memory and Aging Project cohort found that 
the MIND diet was associated with significantly slower cognitive decline on global 
cognitive scores over 4.7 years of follow-up and  35-53% reduction in risk of AD among 
those with the middle and highest tertiles of MIND adherence compared to those in the 
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lowest.201,202 As with the Mediterranean and DASH diets, there is a consistent statistically 
significant association between diet and dementia. 
Physical Activity 
 Several controlled trials, primarily with aerobic exercise interventions such as 
walking or biking, have shown physical activity improves cognitive function or 
hippocampal volume after relatively short follow-up (4 weeks to 1 year).203 A meta-
analysis of 37 prospective cohort studies found that the highest levels of physical activity 
were associated with slower cognitive decline compared to the lowest levels of physical 
activity (RR: 0.65; 95% CI: 0.55, 0.76) as well as reduction in dementia risk (RR: 0.86; 
95% CI: 0.76, 0.97).204 The evidence consistently points to habitual physical activity as a 
potential protective factor against cognitive impairment. Ideal physical activity for 
improvement or maintenance of cognitive function has been identified as aerobic exercise 
lasting at least 20-30 minutes per session with sustained increase in heart rate and need 
for oxygen that, over time, leads to improved cardiovascular fitness (measured by peak 
oxygen consumption per unit time).205 
Loss of muscle strength and mass (sarcopenia) are common, natural parts of the 
aging process that limits independence in older adults.206 These processes are accelerated 
by lack of physical activity putting individuals at greater risk of immune system 
dysfunction, metabolic disease, musculoskeletal disorders, falls, cancer, and neurological 
disorders.206 Little is known about the mechanisms that may facilitate any protective 
effects of physical activity on the brain. One hypothesis suggests that age-related 
reduction in levels of growth factors such as brain-derived neurotrophic factor (BDNF) 
correlate with decline in hippocampal volume and elevated memory deficits. Evidence 
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suggests aerobic exercise in older adults can increase BDNF levels, increase the size of 
the anterior hippocampus, improve spatial memory, and increase plasticity of brain 
networks (frontal executive, fronto-parietal, primary motor cortex, and primary auditory 
cortex).206-209 This response to exercise is thought to be mediated by insulin-like growth 
factor (IGF-1) because blood levels and brain uptake of IGF-1 are elevated with exercise, 
and it is the first biochemical pathway shown to influence brain aging.206,210,211  
3.6. Summary 
 Demographic, genetic, vascular, and behavioral risk factors implicated in 
dementia heavily overlap to those implicated in CVD and vary in strengths of their 
associations (Table 3.3). A recent study assessing the association between the American 
Heart Association’s Life’s Simple 7 metrics of smoking, physical activity measures, diet 
measure, BMI, total cholesterol, blood pressure, and fasting plasma glucose found that 
risk of dementia decreased by approximately 10% with each metric at recommended or 
ideal levels [hazard ratio (95% CI): 0.90 (0.84, 0.97) per additional metric].212 An optimal 
Life’s Simple 7 score was also associated with slower rate of global cognitive decline.212 
In fact, over half the burden of AD (the most common cause of dementia) has been 
attributed to modifiable risk factors including diabetes, hypertension, obesity, physical 
inactivity, depression, smoking, and low educational attainment.213 In the U.S., these risk 
factors have a combined population attributable risk of 52.7% (95% CI: 25.9%, 72.8%) 
reduced to 30.6% (95% CI: 14.5%, 45.3%) when adjusted for lack of independence 
between risk factors.213 The CAIDE Dementia Risk Score was developed using data from 
the Cardiovascular Risk Factors, Aging, and Dementia (CAIDE) Study in Finland and 
identified age, sex, education, systolic blood pressure, BMI, total cholesterol, physical 
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activity, and ApoE4 carrier status as significant predictors (AUC: 0.78 and 95% CI: 0.72, 
0.84) of 20-year risk of cognitive impairment and decline.214 Because there is no known 
treatment for dementia, identifying modifiable risk factors for individual intervention, 
such as treatment for hypertension and hypercholesterolemia, is important. Further, 
educational public health interventions could be used to encourage physical activity and 
Mediterranean-like diets, while policy and environmental public health interventions 
could be used to reduce structural discrimination that leads to systemic disadvantage for 
minorities and those with low SES. In sum, MCI and dementia prevention will have to 
focus on primordial and primary prevention strategies.  
 
Table 3. 3. Summary of risk factors for MCI and dementia and clinical trial evidence, 
direction of risk, and strength of association 
Risk Factor 
Clinical Trial Evidence 
Supporting Improved 
Cognition through 
Intervention 
Strength of 
Association 
Advanced Age - 
Strong 
 
ApoE4 carrier - 
Hypertensiona SHEP
215, Syst-Eur216, 
PROGRESS217, SCOPE218 
African American or 
Hispanic - 
Obesity None 
Moderate 
 
Physical Inactivityb FABS
219, FINGER220, Train the 
Brain221, DAPA222 
Diet (Mediterranean, 
DASH, or MIND reduce 
risk)c 
FINGER220, PREDIMED223, 
Wardle, et al.224 
Diabetes None 
Hypercholesteremiad ADCS225, LEADe226, ADCLT227 
Female Sex - Weak Tobacco Smoking None 
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Moderate Alcohol 
Consumption (reduces risk) None 
a Antihypertensive medication given to patients with hypertension 
b Physical activity intervention included aerobic exercise or a combination of aerobic and 
anaerobic exercise 
c FINGER Trial: Diet intervention based on Finnish Nutrition Recommendations; 
PREDIMED Trial: Diet intervention based on a Mediterranean diet; Wardle, et al.: Diet 
intervention based on a low-fat diet arm and a Mediterranean diet arm 
d Trial interventions with statins was conducted on those with mild to moderate 
Alzheimer’s disease and normal blood cholesterol levels  
43 
 
CHAPTER 4. STUDY DESIGN: ATHEROSCLEROSIS RISK IN COMMUNITIES 
(ARIC) STUDY COHORT 
4.1. Overview 
Funded by the National Heart, Lung, and Blood Institute (NHLBI), the 
Atherosclerosis Risk in Communities (ARIC) study cohort was developed as a 
prospective epidemiologic investigation of the etiology and natural history of 
atherosclerosis in four U.S. communities.228 Since it began in 1987, the study has 
expanded to include research of the heart, kidneys, and brain in addition to cardiovascular 
risk factors, medical care, and disease by race, gender, location, and time.229 The focus of 
this dissertation is dementia and MCI using neurocognitive data from the ARIC 
Neurocognitive Study (ARIC-NCS). ARIC-NCS is an ancillary study that was integrated 
into regular ARIC clinic examinations as a way to determine the prevalence of cognitive 
impairments and their association with mid-life vascular risk factors as well as track 
cognitive change and identify genetic markers and cerebral imaging features of dementia 
and MCI. 
4.2. Study Design and Population  
ARIC is a multi-center prospective cohort study that enrolled 15,792 participants 
between 1987 and 1989.229 The study has completed six visits, visit 1 (1987-89), visit 2 
(1990-92), visit 3 (1993-95), visit 4 (1996-98), visit 5 (2011-13), visit 6 (2016-17), with 
visit 7 ongoing (2018-19).229 Predominantly white (73%) and African American (27%) 
participants ages 45-64 were enrolled using probability sampling from defined 
populations in Forsyth County, North Carolina, Jackson, Mississippi, the northwestern 
suburbs of Minneapolis, Minnesota, and Washington County, Maryland.228 Only African 
44 
 
American participants were recruited from Jackson, while the participants from 
Minneapolis and Washington County were overwhelmingly white.228 Forsyth County 
included both whites and African Americans.228  
 After IRB approval and informed consent, participants were invited to attend the 
seven clinic visits, and various ancillary studies, from 1987 through the present (Figure 
4.1 and Table 4.1).  These visits typically lasted 3-6 hours and included comprehensive 
physical examinations, interviews on social, demographic, and medical histories, and 
imaging. Of note, if a participant could not attend a clinic visit, they were not censored, 
but had the opportunity to participate in subsequent exams.230 To encourage continued 
attendance and gather data between visits, annual or semi-annual follow-up calls have 
been conducted since ARIC began.229 
 
Figure 4. 1. ARIC visits and follow-up calls from 1987-present, adapted from the ARIC 
website229 
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Table 4. 1. Summary of ARIC-NCS clinic exams and components from 1987-present229 
ARIC & Neurocognitive (NCS) Design Overview 
Exam ARIC Initial Contract Visits ARIC-NCS Visits Visit 1 Visit 2 Visit 3 Visit 4 * Visit 5* Visit 6 Visit 7* 
Calendar 
year 
1987-
1989 
1990-
1992 
1993-
1995 
1996-
1998 
2011-
2013 2016-2017 2018-2019 
Follow-up, y 0 3 6 9 25 30 32 
Age range, y 45-64 48-67 51-70 54-73 71-90 75-94 77-97 
Cohort Size 
Alive, n 15,792 15,305 14,821 14,351 10,152 8,403 6,895 
Surveillance 
(CHD, 
Dementia), n 
   12,928 9420 7353 6206 
Seen in clinic, 
n 15,792 14,348 12,887 11,656 6,538 4,003 ~3,450 
Vascular Risk Factors and Markers 
Completed X X X X X X X 
Imaging 
Systemic Carotid IMT 
Carotid 
IMT 
Carotid 
IMT 
Carotid 
IMT 
Echo, 
PWV PWV 
Echo, 
[Ocular CT, 
CAC] 
Brain MRI   1,929  1,950+ ~1,000 
Brain PET 
(amyloid) 
    346 ~315 
Cognitive Function 
Core tests  X X X X X X 
Full battery (1 
hour) 
    X X X 
Informant 
interviews 
    X X X 
 
4.3. Neurocognitive Study (NCS) 
 During visit 2 (1990-92), a 3-instrument cognitive battery was introduced to 
assess cognitive function.231 The Delayed Word Recall Test (DWRT), Digit Symbol 
Substitution Test (DSST), and Word Fluency Test (WFT) were administered in a quiet 
room in a standardized order by trained interviewers (Table 4.2).231,232 To ensure 
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consistent administration, interviewer performance was monitored by taping and 
reviewing a sample of testing sessions as well as confirming no systematic differences in 
mean test scores administered by different interviewers.231 These three tests were 
administered at visits 2, 4, 5, 6, and 7; however, at visit 5, the ARIC-NCS battery was 
expanded to include the Logical Memory Test, Incidental Learning Test, Animal Naming 
Test, Boston Naming Test, Trail Making Test, Digit Span Backwards Test, Smell Test, 
and Mini-Mental State Exam (MMSE) (Table 4.2) using standardized protocols.232 For 
comparison, test scores (with the exception of the MMSE) were converted to z-scores by 
subtracting the test mean from each participant’s individual score and dividing by the test 
standard deviation.229 For longitudinal comparisons, z-scores were standardized to visit 2 
for the original 3-instrument battery (DWRT, DSST, WFT) or visit 5 for the newly added 
cognitive tests.229  
 
Table 4. 2. Description of cognitive tests administered as part of ARIC-NCS, 1990-
2017229,231,232 
Cognitive 
Test 
Visits 
Administered 
Cognitive 
Domain Overview of Test 
Delayed 
Word 
Recall 
2, 4, 5, 6, and 
7 Memory 
Participants are presented with 10 
nouns and asked to use them in a 
sentence. After a 5-minute delay, 
participants were given 60 seconds 
to recall the 10 words. 
Digit 
Symbol 
Substitution 
2, 4, 5, 6, and 
7 
Sustained 
Attention and 
Processing 
Speed 
This test was adapted from the 
Wechsler Adult Intelligence Scale-
revised (WAIS-R). Participants 
were asked to translate numbers to 
symbols using a key.  
Word 
Fluency 
2, 4, 5, 6, and 
7 
Language and 
Verbal Fluency 
Participants are asked to generate as 
many words (no proper nouns) as 
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they can beginning with the letters 
F, A, and S. They are given 60 
seconds for each word. 
Logical 
Memory 5, 6, and 7 Memory 
Participants are read two short 
stories and asked to recall the 
details after each reading. A filled 
delay of 20-minutes occurs, after 
which, participants are asked to 
recall the details of the two stories. 
Incidental 
Learning 5, 6, and 7 Memory 
After completion of the DSST, 
participants are asked to remember 
the symbols and corresponding 
digit-symbol pairs. (Participants are 
not asked to memorize the digit-
symbol pairs for DSST) 
Animal 
Naming 5, 6, and 7 
Language and 
Verbal Fluency 
Participants are asked to name as 
many animals as they can in 60 
seconds. 
Boston 
Naming 5, 6, and 7 
Language and 
Verbal Fluency 
Participants are shown 30 line 
drawings, on at a time, and given 20 
seconds to name the object in each 
drawing. 
Trail 
Making 5, 6, and 7 
Sustained 
Attention and 
Processing 
Speed 
This test has two parts, A and B. In 
part A, participants are given 
numbered dots “1-25” dispersed 
around a page and must draw lines 
connecting the numbers 
sequentially. In part B, participants 
are given numbers “1-13” and 
letters “A-L” and asked to draw 
lines connecting the number and 
letters sequentially, but alternating 
with a number then letter. 
Digit Span 
Backwards 5, 6, and 7 
Sustained 
Attention and 
Processing 
Speed 
The interviewer reads a series of 
numbers increasing in length from 
2-7 digits each. Participants are 
asked to repeat each number series 
backwards. 
Smell Test 5, 6, and 7 Sensory and Motor Function 
Participants are presented with 12 
odorous pens and asked to identify 
the smell in a multiple-choice 
format. 
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Mini-
Mental 
State Exam 
5, 6, and 7 All 5 domains 
The MMSE was developed to be a 
fast, standardized screening 
instrument for a number of 
cognitive impairments.  
  
After the cognitive battery, participants meeting the following criteria were 
invited to participate in the second stage of the ARIC-NCS exam: 1) low score on the 
MMSE (defined as an MMSE score of <21 for whites or <19 for African Americans) or 
2) a low cognitive test z-score (defined as falling at or below the worst 20th percentile of 
change or below the worst 10th percentile of score on at least one test). In addition, a 
small proportion (approximately 10%) of cognitively “normal” participants were 
randomly chosen to participate in the second stage as a comparative sample. Informants 
were used to provide information on the behaviors and functional ability if an ARIC 
participant was suspected of being cognitively impaired. This portion of the exam also 
included physical and neurological examinations where participants were given the 
Unified Parkinson’s Rating Scale (used to assess motor and non-motor symptoms of PD), 
the Clinical Dementia Rating (CDR) subject (as well as CDR informant if an informant 
was present), and the Hachinski Ischemic Scale (a questionnaire used to diagnose 
VaD).233,234 In addition, retinal photographs were taken, a neuropsychiatry inventory was 
taken, neurological and dementia history were collected, and participants were asked 
about their neurological family history. Finally, stage two attendees were asked to 
provide informed consent to participate in the final stage of the ARIC-NCS exam, which 
included cerebral magnetic resonance imaging (MRI) from which primary and secondary 
etiology was identified. Of note, at visits 6 and 7, participants suspected of being 
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cognitively impaired underwent a second stage of testing, but, unlike visit 5, this portion 
of the exam did not included the Unified Parkinson’s Rating Scale, Hachinski Ischemic 
Scale, nor was etiology of suspected dementia cases identified. 
Dementia and MCI Classifications and Adjudication 
  Based on the data collected through ARIC-NCS, annual/semi-annual follow-up 
calls, and surveillance of hospital discharge codes and state and national death records, 
MCI and dementia cases were identified based on the quality of data available (Table 4.3 
and Table 4.4). The first level, involved adjudicated cases identified during ARIC-NCS 
at visits 5 (2011-13) or 6 (2016-17) and included the longitudinal cognitive assessments 
from visits 2, 4, 5, and 6.83 A standardized definition for dementia and MCI was used for 
level 1 classification to generate computer algorithmic diagnoses; a panel of physicians 
and neuropsychologists then reviewed each case of suspected cognitive impairment as 
well as a random sample of cognitively normal participants.83  
 Level 2 dementia and MCI included cases identified in level 1 as well as 
participants who did not attend ARIC-NCS and were identified through the modified 
telephone interview for cognitive status (TICSm), informant telephone interview using a 
modified version of the Clinical Dementia Rating (CDR: Informant), and a random 
sample used to correct for missed cases.83 Telephone screening began in 2011 and 
primarily identified cases during visits 5 and 6 among participants who could not attend 
the ARIC-NCS visit or a home visit.83 Finally, level 3 included levels 1 and 2 as well as 
participants identified through surveillance for hospitalization discharge codes (ICD-9 or 
ICD-10) or death certificate codes related to dementia. These cases were primarily 
identified prior to visit 5.83 Overall, MCI cases could only be identified among 
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participants who attended ARIC-NCS visits (starting at visit 5), whereas dementia cases 
were identified throughout the ARIC follow-up using various methods. 
Due to the varying levels of MCI and dementia cases, separate analyses were run 
using two definitions of dementia and MCI outcomes. The first definition included 
incident dementia cases from visits 1 through 5 or 6 (level 3 criteria). The second 
definition only included adjudicated dementia and MCI cases (level 1 criteria), which 
were identified at ARIC visits 5 and 6 and included information on etiology (AD, CeVD, 
LBD or unknown) determined from participants’ brain MRIs at visit 5).  
 
Table 4. 3. Summary of dementia and MCI cases identified in ARIC, 1987-2016 
 Level 1 
Level 2  
(includes Level 
1) 
Level 3 
(includes Level 
1 and 2) 
Death or Hospital Code  
(prior to Visit 5)   756 
Visit 5 MCI 1366   
Visit 5 Dementia 341 1014 1566 
Visit 6 MCI 759   
Visit 6 Dementia 585 1778 2702 
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Table 4. 4. Summary of etiology of adjudicated dementia and MCI cases (Level 1) at 
ARIC Visit 5, 2011-13 
Etiology Dementia (%) MCI (%) 
Pure AD 72 (22.3) 425 (37.0) 
AD with CeVD 78 (24.2) 299 (26.0) 
AD with LBD 33 (10.2) 100 (8.7) 
AD with other 14 (4.3) 82 (7.1) 
Total Primary AD 197 (61.0) 906 (78.8) 
Pure CeVD 8 (2.5) 14 (1.2) 
CeVD with AD 63 (19.5) 110 (9.6) 
CeVD with LBD 10 (3.1) 9 (0.8) 
CeVD with other 0 (0.0) 2 (0.2) 
Total Primary CeVD 81 (25.1) 135 (11.8) 
Other 19 (5.9) 69 (6.0) 
Unknown 26 (8.1) 40 (3.5) 
Total 323 1150 
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CHAPTER 5. MANUSCRIPT 1: LIFE COURSE SOCIOECONOMIC STATUS 
AND RISK OF DEMENTIA AND MCI  
5.1. Overview 
Introduction 
The biological and behavioral risk factors of Alzheimer’s disease and related 
dementias may be influenced by life course socioeconomic status (LC-SES). Using the 
Atherosclerosis Risk in Communities Study (ARIC), we assessed the associations of 
individual- and neighborhood-level SES across the lifespan with risk of incident 
dementia. 
Methods  
ARIC is a prospective cohort study of white and African American adults initiated 
in 1987-89. Individual- and neighborhood-level SES at various life epochs was assessed 
via a telephone questionnaire in 2001-02 and summarized as a LC-SES score.  Dementia 
diagnosis through 2013 was ascertained using cognitive examinations, telephone 
interviews and hospital and death certificate codes. Cox regression was used to examine 
the relation of individual LC-SES and neighborhood LC-SES with incident dementia in 
race-specific models. 
Results 
The 12,599 participants included in the analysis were 75% white and 25% African 
American with a mean age of 54 ± 5.7 years. A total 1,707 cases of incident dementia 
occurred over a median follow-up of 24 years. After adjustment, each standard deviation 
(SD) greater individual LC-SES score was associated with a 14% (HR (95% CI): 0.86 
(0.81, 0.92)) lower risk of dementia in whites and a 21% (HR (95% CI): 0.79 (0.71, 
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0.87)) lower risk in African Americans. When education was taken out of the individual 
LC-SES score, an SD greater individual LC-SES score was associated with a 10% (HR 
(95% CI): 0.90 (0.84, 0.97)) lower dementia risk in whites and 15% (HR (95% CI): 0.85 
(0.76, 0.96)) lower risk in African Americans. Neighborhood LC-SES was not associated 
with dementia for either group. 
Conclusion 
 Individual LC-SES is an important risk factor for incident dementia in whites and 
blacks, whereas cumulative neighborhood LC-SES is not. Future research is needed to 
identify critical periods over the life course where SES factors have the greatest effect on 
dementia risk and further examination of neighborhood-level SES using a LC-SES model 
is needed. 
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5.2. Background 
 There is increasing evidence that chronic diseases in older adults are caused by a 
complex accumulation and interaction of lifetime exposures.235  Socioeconomic status 
(SES), also referred to as socioeconomic position, reflects the “social and economic 
factors that influence which positions individuals or groups will hold within the structure 
of a society.”48 SES collected across the life course can be used to quantify the 
accumulation of risk factors over the progression of life epochs.236,237 Life epochs can be 
measured at the individual- and neighborhood-levels and generally include childhood, 
young adulthood, active professional life, and older adulthood (Table 5.1). Life course 
SES (LC-SES) models hypothesize that life epochs do not occur independently of one 
another, but events occurring during these periods can accumulate and interact leading to 
increased risk of chronic disease over a lifetime.236,237 
 
Table 5. 1. Examples of SES measures at different life epochs.236,237 
Life Epoch Example SES Measures 
Childhood 
Birthweight, Parent’s education, Parent’s occupation, 
Household income, Household conditions, Overcrowding 
Young Adulthood Education 
Active Professional Life 
Occupation, Household income, Employment status, 
Wealth, Partner’s SES, Household conditions 
Retirement/Older 
adulthood  
Household income, Wealth/deprivation, Household 
conditions 
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 SES is an especially crucial component in the development of dementia due to the 
importance of cognitive reserve.36 The concept of cognitive reserve reflects the 
observation that cognitive function does not always correspond to observable brain 
pathology.36 While there is no standard measure of cognitive reserve, measures of SES 
and education are widely used proxies, because they signify beneficial environmental 
exposures.36 Further, Alzheimer’s disease and related dementias have biological and 
behavioral risk factors whose associations may be confounded or modified by SES.238 
For instance, confounding of associations between mid-life vascular risk factors and 
incident dementia by SES may not be eliminated by adjustment for mid- or late-life SES 
alone.124,239,240 We are interested in characterizing the association between LC-SES and 
dementia at the individual and neighborhood levels, assessing separately the potential 
effects of economic versus educational dimensions of SES.  
 A number of studies have found a significant inverse association between 
individual-level SES and cognitive decline and dementia (Table A.1).55,102,129,241-252 
However, the methods used to measure SES have varied widely among studies, and many 
relied on SES measured only during middle age or later adulthood. Taking a life course 
approach to understanding dementia is important in order to better classify risk factors 
that may have cumulative effects on disease risk but are masked (partially or fully) by 
examining one life epoch only.237,239 Among studies that have assessed LC-SES and 
cognitive function, very few have measured both individual and neighborhood-level SES. 
Neighborhood SES adds context to individual SES and may independently influence 
dementia risk through physical and social characteristics of neighborhoods that contribute 
to disparities and influence individual behaviors and stress levels.253  
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 Using the African American and white participants of the ARIC-NCS cohort, we 
hypothesized that higher LC-SES was inversely associated with risk of incident dementia, 
with both higher individual- and neighborhood-level LC-SES independently contributing 
to lower dementia risk. We also hypothesized economic measures of LC-SES would be 
associated with lower risk of dementia independent of education. In addition to 
evaluating LC-SES, we report associations of SES at three life epochs (i.e. childhood, 
young adulthood, middle/older adulthood) with incident dementia risk. 
5.3. Methods  
 The ARIC-NCS cohort was used to prospectively examine the association 
between cumulative LC-SES (childhood through older adulthood) and dementia 
outcomes from visit 1 (1987-89) through visit 5 (2011-13). In addition, participants were 
followed continuously for hospitalizations and mortality. For our analysis, incident 
dementia was ascertained from visit 1 (1987-89) through visit 5 (2011-13).  Participants 
were excluded if they were not white or African American or African Americans from 
Maryland or Minnesota (n=93), they did not participate in the LC-SES ancillary study 
(2001-2002) (n=2,626), they developed dementia before the questionnaire was 
administered (n=141), or they were missing baseline covariates (n=323). After 
exclusions, 12,599 participants were included in the analysis. 
Individual- and neighborhood-level LC-SES data were obtained using 
questionnaires administered over the phone in 2001-02. Questions evaluated SES factors 
including education, occupation, occupational role, home ownership, income, and wealth 
over three life epochs: childhood (approximately age 10 – SES pertained to parental 
SES), young adulthood (approximately age 30), and middle/older adulthood (ages 45-64 
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when participants entered the ARIC study) (Table 5.2). Cumulative individual-level LC-
SES scores were created by summarizing SES variables related to the three epochs 
following an approach developed by Carson, et al. 2007.254 For individual LC-SES, 
variables related to each epoch had a range of possible values between 0 (lowest SES) 
and 5 (highest SES).254 These epoch scores were summed to get a cumulative individual 
LC-SES score ranging between 0 and 15.254 We also assessed cumulative individual LC-
SES without education by removing individual level educational attainment from the 
score (keeping in parental education). We then adjusted for educational attainment 
separately in the models to determine whether economic factors of SES were associated 
with dementia independent of individual educational attainment.  
Neighborhood-level LC-SES variables were identified in a factor analysis from 
available census data covering the three life epochs and representing several decades.254 
Z-scores were calculated by subtracting individual neighborhood SES variable measures 
(derived from census tract data at each epoch) from the group mean and dividing by the 
standard deviation. Because of the potential impact of segregation on SES and different 
racial distributions across the four ARIC field centers, race-specific z-scores were 
obtained for each census variable and summed to develop a summary z score for 
cumulative neighborhood LC-SES where a higher z score indicated higher SES.254 We 
created race-specific, distribution-based tertiles of the cumulative neighborhood-level 
LC-SES score for analysis. 
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Table 5. 2. Individual and neighborhood life course socioeconomic factors and scoring 
adapted from Carson AP, 2007254 
Individual LC-SES Life Epoch Neighborhood LC-SES 
Variable Score Variable Z-Scorea 
Parental 
Education 
<8th grade = 0 
Childhood 
(age 10) 
Adult 
Education 
Proportion 
with H.S. or 
College degree 
8th grade = 1 
>8th grade = 2 
Parental 
Occupation 
Manual = 0 Adult 
Occupational 
Role 
Proportion 
with 
managerial 
roles 
Non-manual = 1 
Parental 
Occupational 
Role 
Non-managerial = 
0 Dwellings Occupied by 
Owner 
Proportion of 
homes 
occupied by 
owner  Managerial = 1 
Parental 
Home 
Ownership 
Rent or other = 0 Log Median 
Home Value 
Median value 
of homes  Own home = 1 
Education 
<High school = 0 
Young 
Adulthood 
(age 30 
years) 
Adult 
Education 
Proportion 
with H.S. or 
College degree 
High school = 1 
>High school = 2 
Occupation 
Manual = 0 Adult 
Occupational 
Role 
Proportion 
with 
managerial 
roles 
Non-manual = 1 
Occupational 
Role 
Non-managerial = 
0 Log Median 
Income 
Median family 
income  Managerial = 1 
Home 
Ownership 
Rent or other = 0 Dwellings 
Occupied by 
Owner 
Proportion of 
homes 
occupied by 
owner 
Own home = 1 
  Log Median Home Value 
Median value 
of homes  
Income 
<$25,000 = 0 
Middle/Older 
Adulthood 
(age 45-64 
years) 
Adult 
Education 
Proportion 
with H.S. or 
College degree 
$25-34,999 = 1 
>$35,000 = 2 
Occupation 
Manual = 0 Adult 
Occupational 
Role 
Proportion 
with 
managerial 
roles 
Non-manual = 1 
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Occupational 
Role 
Non-managerial = 
0 Log Median 
Income 
Median family 
income Managerial = 1 
Home 
Ownership 
Rent or other = 0 Dwellings 
Occupied by 
Owner 
Proportion of 
homes 
occupied by 
owner 
Own home = 1 
  Median Home Value 
Median value 
of homes  
  
Households 
with Passive 
Income 
Proportion 
with income 
besides 
wages/salary 
aValues for z-scores derived from census tract data representing the location a participant 
reported living during each epoch 
 
Covariate information was collected at baseline (visit 1; 1987-1989) and included 
age, sex, ApoE4, body mass index (BMI), tobacco smoking status, hypertension, diabetes, 
alcohol drinking status, HDL cholesterol, and total cholesterol. BMI was calculated from 
measured weight and height (kg/m2). Hypertension was defined as having a systolic 
blood pressure > 140 mm Hg, diastolic blood pressure > 90 mm Hg, or self-report of 
antihypertensive medication use. Diabetes was defined as non-fasting serum glucose ≥ 
200 mg/dL, fasting glucose ≥ 126 mg/dL, self-report of diabetes diagnosis from a 
physician, or report of taking medication for diabetes or high blood sugar.  
Dementia and MCI cases were identified from ARIC-NCS clinic examinations 
conducted at visit 5, surveillance of hospital and death certificate codes, and annual and 
semi-annual telephone-based cognitive assessments. Methods are described in detail in 
Chapter 4. Our primary analysis included all incident dementia cases available in ARIC 
between visits 1 and 5. This included cases identified using surveillance of hospital and 
death records, informant interviews for deceased participants suspected to have had 
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dementia, annual and semi-annual telephone follow-up calls with the administration of 
the modified telephone interview for cognitive status (TICSm) to participants who were 
alive and did not attend visits 5, and adjudicated dementia identified in ARIC-NCS. We 
conducted a secondary analysis using only adjudicated dementia and MCI cases 
identified in ARIC-NCS at visit 5. Dementia surveillance is believed to be relatively 
complete, but because analyses of MCI required attendance at visit 5, there was likely 
informative censoring of participants over the follow-up period.83 To account for this 
potential selection bias, we used inverse probability of attrition weights (IPAW) in our 
analyses of adjudicated cases.83,255 
Statistical Analysis 
 Individual- and neighborhood-level LC-SES measures were ascertained 
retrospectively causing several variables to have missing data. The amount of missing 
data for individual LC-SES variables was around 14%. For neighborhood LC-SES, the 
amount of missing data was approximately 25% and primarily due to changes in census 
questions over several decades. To address this issue, we used multiple imputation by 
chained equations (MICE)256 to impute individual- and neighborhood- level LC-SES 
scores. We created 10 sets of imputations to obtain a series of data points taking into 
account within- and between-variance of each imputation. We then used the average of 
the multiple imputed values for analysis. 
 We described prevalences and means of baseline covariates and individual LC-
SES. Incidence rates of dementia between visits 1 (1987-89) and 5 (2011-13) stratified by 
life epoch (childhood, young adulthood, and middle/older adulthood) and race-specific, 
distribution-based individual LC-SES tertiles were estimated using Poisson regression. 
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Cox regression was used to assess the association between cumulative LC-SES and risk 
of dementia. We modeled LC-SES in three ways: i) cumulative individual-level LC-SES 
score, ii) cumulative individual-level LC-SES score after removing education and 
adjusting for education separately in the model, and iii) cumulative neighborhood LC-
SES score with adjustment for cumulative individual LC-SES score separately in the 
model. To account for clustering of individual-level SES within neighborhood, we also 
ran a Cox regression with a random effect for neighborhood-level LC-SES. This design 
effect was of small magnitude and did not visibly affect individual LC-SES estimates so 
is not presented.  
 Two models were tested for each of the Cox analyses. Model 1 was adjusted for 
age, sex, and ApoE4 status. Model 2 was adjusted for model 1 covariates plus baseline 
BMI, hypertension, diabetes, HDL cholesterol, total cholesterol, alcohol drinking status, 
and tobacco smoking status. We used a restricted cubic spline model to investigate the 
continuous non-linear relation between cumulative individual-level LC-SES and hazard 
of dementia with knots specified at the 5th, 50th, and 95th percentiles. To test the 
proportional hazards assumption, we included an interaction term between each LC-SES 
measure and log follow-up time, and the assumption was met. The analysis was re-run 
without applying MICE procedures to impute missing LC-SES data and results were 
similar.  
As a secondary analysis, we used relative risk regression with a Poisson 
distribution, log link, and inverse probability of attrition weights (IPAW) to assess the 
association between LC-SES modeled three ways and risk of adjudicated dementia and 
MCI at visit 5. However, adjudicated dementia and MCI cases could only be identified in 
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participants that attended visit 5. These participants were generally healthier, had higher 
SES, and were more likely to be white than participants that refused to attend or died 
prior to this exam likely biasing the analyses.230 Because of these issues with bias, results 
of our adjudicated analyses are presented in Tables A.2 and A.3 of the Appendix and 
results presented here only discuss risk of incident dementia. 
All statistical analysis were conducted using SAS 9.4 (SAS Inc., Cary, NC). 
5.4. Results 
 Among the 12,599 participants included in the analysis, 9,675 (75%) were white 
and 3,248 (25%) were African American with a mean age of 54 ± 6 years at baseline 
(1987-89). African Americans at baseline were more likely than whites to carry the 
APOE ε4 allele, have not attained high school completion, have a family income of less 
than $25,000, smoke tobacco, be non-drinkers, have a higher BMI and HDL cholesterol, 
and have prevalent hypertension and diabetes (Table 5.3). African Americans also had a 
lower cumulative individual-level LC-SES score than did whites (Table 5.3).    
A total 1,707 cases of incident dementia occurred (1,170 cases in whites and 537 
cases in African Americans) over a median follow-up of 24.3 years. In both African 
Americans and whites after adjustment for age, sex, and ApoE4 status, being in the 
lowest race-specific tertile of individual LC-SES at each life epoch (childhood, young 
adulthood, and middle/older adulthood) was associated with the highest incidence of 
dementia, followed by the middle SES tertile, and then the highest SES tertile (Figure 
5.1). In both races, these differences in the incidence rates of dementia by individual SES 
tertile were statistically significant for young and middle/older adulthood, but not for 
childhood. Among whites, low young adulthood SES was associated with a 36% [RR 
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(95% CI): 1.36 (1.18, 1.56)] greater dementia risk compared to high young adult SES. 
Low middle/older adulthood SES was associated with a 49% [RR (95% CI): 1.49 (1.25, 
1.76)] greater dementia risk compared to high SES. Among African Americans, low 
young adulthood SES was associated with a 41% [RR (95% CI): 1.41 (1.16, 1.71)] 
greater and low middle/older adulthood SES was associated with a 53% [RR (95% CI): 
1.53 (1.23, 1.90)] greater dementia risk compared to high SES tertiles for each epoch 
respectively. There was also a statistically significant interaction between SES tertile and 
race for each life epoch, indicating a stronger association between low SES and dementia 
in African Americans compared to whites.  
 We also assessed the race-specific associations between dementia and cumulative 
individual LC-SES score as a continuous variable calculating HRs per increment of the 
pooled standard deviation (Table 5.4). Among whites, after model 1 adjustments, a 
standard deviation greater cumulative individual LC-SES score was associated with a 
17% lower risk of dementia [HR (95% CI): 0.83 (0.77, 0.88)].  The association was 
slightly attenuated after additional model 2 adjustments [HR (95% CI): 0.86 (0.81, 0.92)]. 
Among African Americans, a standard deviation greater cumulative individual LC-SES 
score was associated with a 23% lower risk of dementia [HR (95% CI): 0.77 (0.70, 0.85)] 
after model 1 adjustments and HR (95% CI): 0.79 (0.71, 0.87) in model 2.  
We then assessed the association between cumulative individual LC-SES score 
independent of individual educational attainment. Education was removed from the 
cumulative individual LC-SES score calculation (keeping parental education in the score) 
and adjusted for separately in the models (Table 5.4). For whites, a standard deviation 
greater individual LC-SES score without education was associated with a 12% lower risk 
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of dementia [HR (95% CI): 0.88 (0.82, 0.95)] that weakened slightly with model 2 
adjustments [HR (95% CI): 0.90 (0.84, 0.97)]. In African Americans, a standard 
deviation increment of cumulative individual LC-SES score without education was 
associated with a 14% lower risk of dementia [HR (95% CI): 0.86 (0.77, 0.98)] after 
model 1 adjustment and HR (95% CI): 0.85 (0.76, 0.96) in model 2.  
Using restricted cubic splines to assess the non-linear association between 
cumulative individual LC-SES score and risk of dementia, we found that in both whites 
and African Americans, the association between LC-SES score (with and without 
education) and risk of dementia was linear (Figure 5.2). 
 Finally, we examined the relationship between neighborhood-level cumulative 
LC-SES score in whites and African Americans (Table 5.5). After adjustments, including 
adjustment for cumulative individual-level LC-SES score, there were no statistically 
significant, independent associations between cumulative neighborhood-level LC-SES 
score and dementia after multivariable adjustment (Model 2 HR (95% CI): 1.00 (0.96, 
1.04) in whites and 1.06 (1.00, 1.13) in African Americans). 
5.5. Discussion 
This prospective cohort study of community-dwelling African American and 
white adults followed for 24 years had three main findings.  Higher individual-level LC-
SES was associated in both whites and African Americans with moderately lower 
incidence of dementia; these associations were statistically significant for young 
adulthood and middle/older adulthood SES, and the pattern was similar for childhood 
SES though not statistically significant. After removing education from the individual-
level LC-SES score and adjusting for educational attainment separately, a higher 
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individual LC-SES score was associated with lower risk of dementia, suggesting that 
measures of economic status (income, home ownership, and wealth) may be  associated 
with incident dementia independent of education. Finally, in both whites and African 
Americans, there was no association between cumulative neighborhood-level LC-SES 
score and incident dementia independent of individual-level LC-SES score.  
 The results of this analysis suggest that low cumulative individual-level LC-SES 
is an important risk factor for dementia. While SES can change over the life course, an 
inverse association was seen with incident dementia at each life epoch. These findings 
corroborate previous studies of LC-SES in relation to cognitive decline or dementia, 
which found that, across the life course, markers of high SES were associated with lower 
risk of cognitive impairment in older adulthood.55,102,129,244,249,251,257  
We also found that cumulative individual-level LC-SES was inversely associated 
with dementia independent of individual-level education. While education is an important 
indicator of SES and likely a proxy for cognitive reserve, our findings suggest that other 
(primarily economic) SES factors also contribute to the association between LC-SES and 
dementia. These results mirror what other studies of LC-SES have found: a statistically 
significant, albeit weaker than for education, association between economic factors and 
cognitive impairment independent of education.55,244,251 In studies that used economic 
SES measures from middle or older adulthood only, results have been more mixed with 
some studies finding an association, 246,247,258 but most finding no association.242,243,245,248 
Efforts to reduce risk of dementia at the population level must address economic 
inequalities that are foundational to proximal causes of differences in dementia risk such 
as education.259 
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Finally, the lack of association between cumulative neighborhood-level LC-SES 
and dementia indicates that individual level factors may be more important than 
neighborhood factors in the causation of dementia. These findings corroborate Canadian 
and British cohort studies that found no association between neighborhood-level SES and 
risk of dementia, 246,258 but differ from a Korean study that found that higher 
neighborhood SES was associated with higher cognitive test scores.252 However, all three 
of these studies assessed neighborhood-level factors in mid- or late-life. To our 
knowledge, ours is the only study of cumulative neighborhood-level LC-SES and 
dementia, making this a novel finding. Further examination of the relation between 
neighborhood SES and dementia is needed, particularly neighborhood-level LC-SES. In 
addition, there is evidence that neighborhood-level environmental factors related to SES, 
such as lead exposure and air pollution, increase dementia risk.260-262  
Our study has several strengths including a large sample size and number of 
dementia cases, a long follow-up period, and the ability to incorporate SES over the 
entire life course. By not having to rely on mid- or late-life SES measures, we could 
account for SES over the entire latency period of dementia, which is believed to span 
multiple decades.15 The LC-SES approach allowed for adjustment for the cumulative 
effect of SES, without making assumptions about relative importance of individual 
epochs. In addition, no studies have previously examined the relation between 
neighborhood level LC-SES and dementia or how neighborhood and individual LC-SES 
interact.    
Despite our study’s strengths, there are limitations to our analyses. Firstly, in the 
ascertainment of dementia cases, selection bias related to censoring and death over 
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follow-up may have occurred and distorted hazard ratio estimates. To reduce selection 
bias, the ARIC study used a variety of strategies to completely identify dementia cases 
among participants that did not attend every ARIC visit, including annual follow-up calls 
with telephone interviews for cognitive status and surveillance of hospitals and death 
certificate codes. Secondly, cognitive tests used to identify cognitive decline and 
dementia may lack convergent validity between race groups due to cultural biases and 
socioeconomic differences.80,84 Race-specific analysis were conducted to minimize race-
related differences in validity of cognitive testing that may be related to SES and cultural 
background. Further, by using race-specific analyses, we avoided issues of comparison 
and differences in attainable LC-SES over the lifetimes of whites and African Americans 
that would be inhibited by segregation and discrimination. However, there may still be 
issues of generalizability due to lack of geographic variability in ARIC, given that 
African Americans were from Mississippi and North Carolina while white participants 
were from Minnesota, Maryland, and North Carolina. 
A third limitation was that individual and neighborhood LC-SES data relied on 
participants’ knowledge and ability to remember, at mid-life, the conditions they 
experienced during childhood and early adulthood. While memory may not be precise, in 
measuring SES, the significance is in identifying where in the hierarchy of social position 
an individual fell relative to others like them. This means that precise measurement was 
not as important as relative knowledge of one’s circumstances, which were not likely 
forgotten. A fourth limitation was that missing data, particularly within neighborhood-
level LC-SES variables, required MICE methods, but a sensitivity analysis without the 
imputed values yielded similar results.  
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Our longitudinal analysis indicates that incident dementia is inversely associated 
with individual-level LC-SES whereas neighborhood-level LC-SES is not associated. 
Future research is needed to identify critical periods over the life course where SES 
factors have the greatest effect on dementia risk and might warrant targeted intervention 
that aims to enable social and economic opportunities. In addition, further examination of 
neighborhood-level SES factors using a LC-SES model is needed. 
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5.6. Tables and Figures 
Table 5. 3. Baseline characteristics stratified by race, ARIC, 1987-89  
Risk Factors White African American n = 9,570 n = 3,029 
Age, mean 53.9 ± 5.6 52.9 ± 5.7 
Men, % 45.6 35.7 
ApoE4 carriers, % 26.3 39.0 
Basic Educationa, % 15.4 38.0 
Family Income < $25,000b, 
% 14.4 53.5 
Current Tobacco Smoker, 
% 21.8 26.2 
Current Alcohol Drinker, % 65.7 31.2 
BMI, kg/m2 26.9 ± 4.8 29.8 ± 6.1 
Hypertensionc, % 25.3 52.6 
Diabetesd, % 7.5 15.6 
Total Cholesterol, mg/dL 214.2 ± 40.3 214.8 ± 44.7 
HDL Cholesterol, mg/dL 51.1 ± 16.8 55.4 ± 17.1 
Cumulative Individual LC-
SES scoree, units 10.2 ± 2.5 7.5 ± 2.7 
Mean ± Standard Deviation 
aBased on self-report of some high school education or less at visit 1 
bBased on self-report of income at visit 1 
cDefined as diastolic blood pressure > 90 mm Hg, systolic blood pressure > 140 mm Hg, 
or use of hypertensive medication 
dDefined as non-fasting blood glucose > 200 mg/dL, fasting blood glucose > 126 mg/dL, 
self-report of diabetes, or reporting taking medication for diabetes or high blood sugar  
eSES score based on sum of scores from three life epochs, childhood (age 10), young 
adulthood (age 30), and middle/older adulthood (ARIC baseline age 45-64) 
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Figure 5. 1. Incidence rates of dementia stratified by life epoch and race-specific 
individual SES tertiles (low, middle, and high), ARIC 1987-2013 
 
Adjusted for age, sex, and ApoE4 status 
*Statistically significant (p-value < 0.05) difference across life epoch SES tertiles 
Childhood: age 10 
Young adulthood: age 30 
Middle/Older adulthood: ages 45-64 
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Table 5. 4. Hazard ratios (95% CI) of dementia per pooled standard deviation increment 
of cumulative individual LC-SES and cumulative individual LC-SES with education 
removed, ARIC 1987-2013 
Cumulative Individual Life Course SES† 
 White African American 
n total = 9,570 n total = 3,029 
n events = 1,170 n events = 537 
Model 1 HR 0.83* (0.77, 0.88) 
0.77* 
(0.70, 0.85) 
Model 2 HR 0.86* (0.81, 0.92) 
0.79* 
(0.71, 0.87) 
Cumulative Individual Life Course SES with Education Adjusted Separately‡ 
 
White African American 
n total = 9,674 n total = 3,248 
n events = 1,180 n events = 572 
Model 1 
HR 
LC-SES 0.88* (0.82, 0.95) 
0.86* 
(0.77, 0.98) 
Education   
Some High School or 
Less  
1 
(Ref) 
1 
(Ref) 
High School 
Graduate 
0.75 
(0.64, 0.87) 
0.74 
(0.59, 0.92) 
Some College or 
More 
0.74 
(0.62, 0.88) 
0.68 
(0.52, 0.87) 
Model 2 
HR 
LC-SES 0.90* (0.84, 0.97) 
0.85* 
(0.76, 0.96) 
Education   
Some High School or 
Less  
1 
(Ref) 
1 
(Ref) 
High School 
Graduate 
0.80 
(0.68, 0.93) 
0.76 
(0.61, 0.95) 
Some College or 
More 
0.81 
(0.68, 0.96) 
0.74 
(0.57, 0.96) 
*Statistically significant (p-value < 0.05) 
†Pooled standard deviation = 2.80 
‡Pooled standard deviation = 2.29 
Model 1: adjusted for age, sex, and ApoE4 status 
Model 2: adjusted for Model 1 + BMI, hypertension, diabetes, HDL cholesterol, total 
cholesterol, alcohol drinking status, tobacco smoking status 
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Figure 5. 2. Race-specific age, sex, and ApoE4 status adjusted hazard ratio (95% CI) of 
incident dementia in relation to cumulative individual LC-SES with and without 
education, ARIC 1987-2013 
 
A. Association between cumulative individual LC-SES and dementia in whites; B. 
Association between cumulative individual LC-SES and dementia in African Americans; 
C. Association between cumulative individual LC-SES without education and dementia 
in whites; D. Association between cumulative individual LC-SES without education and 
dementia in African Americans 
*Analyzed using restricted cubic splines with knots at the 5th, 50th, and 95th percentiles of 
the individual LC-SES distribution. 
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Table 5. 5. Hazard ratios (95% CI) of dementia per standard deviation† increment of 
cumulative neighborhood LC-SES, ARIC 1987-2013 
 
White African American 
n total = 9,570 n total = 3,029 
n events = 1,170 n events = 537 
Model 1 HR 0.99 (0.95, 1.03) 
1.05 
(0.99, 1.12) 
Model 2 HR 1.00 (0.96, 1.04) 
1.06 
(1.00, 1.13) 
Abbreviation: HR: Hazard ratio; CI: Confidence interval 
†Standard deviation = 1 for whites and African Americans 
Model 1: adjusted for age, sex, ApoE4 status, and cumulative individual LC-SES 
Model 2: adjusted for Model 1 + BMI, hypertension, diabetes, HDL cholesterol, Total 
cholesterol, alcohol drinking status, tobacco smoking status 
  
74 
 
CHAPTER 6. MANUSCRIPT 2: ASSOCIATION OF ABNORMAL THYROID 
FUNCTION WITH DEMENTIA AND MCI 
6.1. Overview 
Background 
Abnormal thyroid hormone levels (high or low) and autoimmunity from 
autoimmune thyroid disease (AITD) may increase dementia risk.  
Methods 
 We examined the associations of thyroid dysfunction or possible AITD in 1990-
92 with dementia through 2017 in the Atherosclerosis Risk in Communities (ARIC) 
Neurocognitive Study.  Thyroid dysfunction (subclinical and overt hypo- or 
hyperthyroidism and euthyroidism) was categorized from serum thyroid-stimulating 
hormone (TSH) and free thyroxine (FT4) cut-points and AITD from anti-TPO antibody 
positivity. Dementia was identified primarily based on cognitive test performance, 
neuropsychological examinations, and clinician review of suspected cases. Additional 
cases of dementia were ascertained through telephone interviews or relevant hospital and 
death certificate codes. Cox regression with multivariable adjustment was used for 
analysis. 
Results 
 After exclusions for missing data, 12,481 participants were included in the 
analysis (mean index exam age 57 ± 5.7 (44% male, 25% black), and 2,235 incident 
dementia cases were identified. AITD was not associated with dementia. Subclinical 
hypothyroidism was associated with a lower risk of dementia [HR (95% CI): 0.74 (0.60, 
0.92] while overt hyperthyroidism was associated a higher risk of dementia [HR (95% 
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CI): 1.40 (1.02, 1.92)] compared to euthyroid participants. Participants with serum FT4 
concentrations above the 95th percentile were at an increased risk of dementia compared 
to those in the middle 90% of FT4 [HR (95% CI): 1.23 (1.02, 1.48)]. 
Conclusions 
 Subclinical hypothyroidism was associated with reduced risk of dementia, 
whereas overt hyperthyroidism, particularly very elevated FT4, was associated with 
increased risk of dementia. The association between subclinical hypothyroidism and 
reduced risk of dementia cannot be explained, but may have been an artifact due to 
chance. By extrapolation, effective treatment of overt hyperthyroidism may modestly 
reduce dementia risk in older adults. 
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6.2. Background 
 The thyroid gland regulates metabolism in adults as part of the endocrine 
system.263 Triiodothyronine (T3) and thyroxine (T4) represent “thyroid hormones” and 
are responsible for regulating cellular energy use affecting almost every organ in the 
body.264,265 T3 and T4 are produced from dietary iodine absorbed through the small 
intestine and circulated to the thyroid where the iodine is concentrated, oxidized, and 
incorporated into thyroglobulin (Tg).266 This process occurs in thyroid epithelial cells that 
form spherical structures called thyroid follicles.264 Thyroid hormone is found in three 
states, stored as droplets within thyroid follicles, bound to carrier proteins circulating in 
the blood, or circulating freely (biologically active) as free T3 (FT3) and free T4 
(FT4).263 T4 comprises 90% of thyroid hormone, though T3 is more biologically 
active.267  
 A negative feedback loop regulates thyroid hormone activity. Thyrotropin-
releasing hormone (TRH) produced in the hypothalamus stimulates the anterior pituitary 
gland to release thyroid-stimulating hormone (TSH).267 TSH, in turn, stimulates release 
of FT3 and FT4 from the thyroid increasing levels of biologically active thyroid 
hormone.267 This change in hormone levels increases metabolism of almost all body 
tissues which can result in increased body temperature, strengthened heartbeat, 
accelerated pulse, increased digestion of macronutrients, and activation of the nervous 
system.263,267 The loop closes when biologically active T3 and T4 act back on the 
hypothalamus inhibiting further TRH release and shutting off the system.267,268 
 Thyroid dysfunction is quite common, especially among older adults, and can 
have serious clinical implications.269 Thyroid function is generally classified as 
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euthyroidism (normal thyroid function), hypothyroidism (underactive thyroid), and 
hyperthyroidism or thyrotoxicosis (overactive thyroid). Elevated TSH and subnormal 
FT4 levels characterize overt hypothyroidism, while elevated TSH with normal FT4 
characterize subclinical hypothyroidism.270 Common symptoms if hypothyroidism 
include dry skin, hair loss, cold sensitivity, fatigue, muscle cramps, and bradycardia.270 
Subnormal TSH and elevated FT4 levels characterize overt hyperthyroidism, while 
subnormal TSH with normal FT4 characterize subclinical hyperthyroidism.271 
Hyperthyroidism symptoms include weight loss, osteoporosis, atrial fibrillation, muscle 
weakness, tremor and neuropsychiatric symptoms.271 See Table 6.1 for prevalence of 
thyroid disorders in the U.S.  
 
Table 6. 1. Prevalence of thyroid dysfunction in those ages >12: NHANES III (1988-
1994).272 
Thyroid Disorder Estimated Prevalence 
Overt Hypothyroidism 0.3% 
Subclinical Hypothyroidism 4.3% 
Total Hypothyroidism 4.6% 
Overt Hyperthyroidism 0.5% 
Subclinical Hyperthyroidism 0.7% 
Total Hyperthyroidism 1.2% 
Total Disorder 5.8% 
  
 Thyroid dysfunction is more prevalent in women compared to men and among 
whites than African Americans.272 Further, average TSH levels and prevalence of anti-
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thyroid antibodies, indicators of autoimmune thyroid disorder, are higher in women 
compared to men (a disparity that increases with age) and higher among whites than 
African Americans.272 While thyroid dysfunction is common, most cases are subclinical. 
 In iodine-replete countries like the U.S., autoimmune thyroid disease (AITD) is 
the most common cause of thyroid dysfunction with an estimated prevalence of 5%.273 
AITD is caused by an immune attack on the thyroid and results in infiltration of the 
thyroid tissue by lymphocytes.273 A combination of genetic susceptibility and 
environmental factors, including radiation, smoking, infection, stress, and drugs, can 
trigger the autoimmune response.273,274 The two main clinical presentations of AITD are 
Grave’s disease (GD), which presents clinically as hyperthyroidism, and Hashimoto’s 
thyroiditis (HT), which presents clinically as hypothyroidism.273 All forms of AITD are 
associated with the presence of serum thyroid peroxidase (TPO) and thyroglobulin (Tg) 
antibodies, though the presence of antibodies does not necessitate disease.275,276 Anti-
TPO antibodies are more common and a stronger indicator of thyroid disease than anti-
Tg antibodies.276 Anti-TPO antibodies are prevalent in 90-95% of AITD patients and an 
estimated 17% of women and 9% of men without known AITD.275,276 
 Thyroid dysfunction can cause a range of mood and cognitive disturbances, 
especially in severe cases. Hypothyroidism is associated with increased rates of anxiety 
and depression as well as mild to moderate deficits in memory and executive function.277 
Hyperthyroidism can also cause anxiety and depression as well as irritability, agitation, 
and deficits in concentration and executive function.277 Increased screening and better 
treatment has reduced the rate of thyroid-related cognitive symptoms by reducing the 
incidence of severe disorder and reversing cognitive symptoms with effective 
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treatment.277 Despite these advancements, there is still interest in the relationship between 
thyroid disorder and dementia due to the thyroid’s well-established influence on brain 
development and function including neuronal maturation and myelination.278,279  
 There are two mechanisms by which thyroid disorders may be associated with 
dementia: action of abnormal thyroid hormone concentrations (high TSH causing low 
FT4 or high FT4 causing low TSH) on the brain causing impairment280 or autoimmunity 
causing AITD and encephalopathy leading to permanent brain damage.281 While some 
studies have found a relation between elevated TSH levels and increased rates of 
dementia or cognitive decline, the literature regarding other thyroid hormones (necessary 
for diagnosing dysfunction) and AITD (measured via anti-TPO positivity) is mixed, 
limited by modest sample sizes (n<3,000), and focused on primarily older participants 
(ages 65 and older at baseline) (Table A.4).278,282-289 Using data from ARIC-NCS, we 
tested the hypothesis that AITD (anti-TPO antibodies) and abnormal thyroid hormone 
(TSH and FT4) levels are associated with increased incidence of dementia over 20 years 
of follow-up. 
6.3. Methods  
 We analyzed the association between thyroid dysfunction and dementia and MCI 
in ARIC-NCS using a prospective cohort study design with baseline at visit 2 (1990-92) 
through visit 6 (2016-17). Participants were excluded from follow-up if they were non-
white or African Americans from MD or MN (n = 103), did not attend visit 2 (n = 1,432), 
had missing serum TSH, FT4, or anti-TPO antibody measures (n = 1,769), or had 
prevalent dementia at visit 2 (n = 4) for a final analytic sample of 12,481 participants. 
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 Thyroid function was assessed using serum samples stored at -70˚C since 
collection at visit 2 that were thawed and tested at Advanced Research Diagnostics 
Laboratory (University of Minnesota) between 2011 and 2013. Assays from Roche 
Diagnostics were used on an Elecsys 2010 Analyzer using a sandwich immunoassay 
method for TSH and competition immunoassay methods for FT4 and ant-TPO 
antibodies.290 Interassay coefficients of variation were < 10%.290 Anti-TPO antibody 
positivity was defined as >34 kIU/L, based on assay manufacturer guidelines.291 Five 
clinical categories (subclinical hypothyroidism, subclinical hyperthyroidism, overt 
hypothyroidism, overt hyperthyroidism, and euthyroidism) were used to define thyroid 
dysfunction based on ARIC-derived cut points associated with thyroid-related genes and 
genetic risk score (Table 6.2).272,291 We also examined categorical variables based on the 
lowest 5%, middle 90%, and highest 5% of TSH and FT4 levels as well as continuously.  
 Covariates included age, sex, race-center (MS-blacks, NC-whites, NC-blacks, 
MN-whites, and MD-whites), ApoE4, income, and education from visit 1 (1987-89). At 
visit 2 baseline (1990-92), BMI, tobacco smoking status, hypertension, diabetes, alcohol 
drinking status, HDL cholesterol, total cholesterol, prevalent cardiovascular disease 
(CVD), and thyroid medication use were measured. BMI was calculated from measured 
weight and height. Hypertension was defined as having a systolic blood pressure > 140 
mm Hg, diastolic blood pressure > 90 mm Hg, or self-report of antihypertensive 
medication use. Diabetes was defined as non-fasting serum glucose ≥ 200 mg/dL, fasting 
glucose ≥ 126 mg/dL, self-report of diabetes diagnosis from a physician, or report of 
taking medication for diabetes or high blood sugar. Prevalent CVD was defined as having 
prevalent stroke, coronary heart disease, myocardial infarction (MI), or atrial fibrillation 
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(AF) at visit 2 ascertained via hospital surveillance, self-report, or detected at an ARIC 
clinic visit (MI and AF), with clinical events other than AF adjudicated by a panel of 
experts.292-295 Participants were asked to bring medication containers for any medication 
taken in the past four weeks prior to each clinic visit, from which thyroid medication use 
was determined at baseline and throughout follow-up.  
 Dementia and MCI cases were identified from ARIC-NCS clinic examinations 
conducted at visits 5 and 6, surveillance of hospital and death certificate codes, and 
annual and semi-annual telephone-based cognitive assessments. Methods are described in 
detail in Chapter 4. Our primary analysis included all incident dementia cases available in 
ARIC between visits 2 and 6. This included cases identified using surveillance of hospital 
and death records, informant interviews for deceased participants suspected to have had 
dementia, annual and semi-annual telephone follow-up calls with the administration of 
the modified telephone interview for cognitive status (TICSm) to participants who were 
alive and did not attend visits 5 or 6, and adjudicated dementia identified in ARIC-NCS. 
We conducted a secondary analysis using only adjudicated dementia and MCI cases 
identified in ARIC-NCS at visits 5 and 6. In this analysis, we also used brain MRI data at 
visit 5, classifying dementia and MCI cases as being CeVD-related if primary or 
secondary CeVD etiology was identified in imaging. Dementia surveillance is believed to 
be relatively complete, but because analyses of MCI required attendance at visits 5 or 6, 
there was likely informative censoring of participants over the follow-up period.83 To 
account for this potential selection bias, we used inverse probability of attrition weights 
(IPAW) in our analyses of adjudicated cases.83,255  
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Statistical Analysis 
 We described means and prevalences of baseline covariates, thyroid hormone 
levels, and AITD status stratified by clinical categories of thyroid dysfunction. To 
characterize the association between abnormal thyroid function and dementia, we used 
Cox regression to assess the hazard of incident dementia between visits 2 and 6 as our 
primary analysis. We modeled thyroid function in several ways: i) anti-TPO antibody 
status (positive/negative); ii) clinical categories of thyroid dysfunction with euthyroidism 
as the reference; iii) categorical TSH and FT4 hormone levels (i.e. 3 categories, 
comparing participants whose hormone levels fell within the middle 90% (reference), 
lowest 5%, and highest 5%); and iv) per standard deviation difference in TSH or FT4 
level.  
 For each analysis, three models were tested. Model 1 adjusted for age, sex, center-
race, ApoE4, income, and education. Model 2 adjusted for model 1 covariates as well as 
BMI, smoking status, hypertension, diabetes, prevalent CHD, drinking status, HDL 
cholesterol, and total cholesterol. Model 3 adjusted for model 2 covariates in addition to 
prevalent CVD and baseline thyroid medication use.  
 Sensitivity analyses were conducted to assess whether taking thyroid medication 
throughout follow-up (versus at baseline) was associated with risk of dementia; however, 
medication use was not associated with dementia and results did not change. We verified 
that the proportional hazards assumption was met by testing the interaction between each 
measure of abnormal thyroid function by log follow-up time. We also used a restricted 
cubic spline model to investigate the continuous non-linear relationship between thyroid 
hormone levels and dementia with knots specified at the 10th, 50th, and 90th percentiles. 
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Hormone levels were truncated at the 1st and 99th centiles to minimize the influence of 
extreme values. 
 As a secondary analysis, we used relative risk regression with a Poisson 
distribution, log link, and IPAW to assess the association between thyroid dysfunction 
and risk of adjudicated dementia and MCI at visits 5 and 6. However, results were null 
likely due to survival bias.296  Adjudicated dementia and MCI cases could only be 
identified in participants that attended visits 5 or 6, and these participants were generally 
healthier, had higher SES, and were more likely to be white than participants that refused 
to attend or died prior to ARIC-NCS exams.230 Because of issues with bias, results of our 
adjudicated analyses are presented in Tables A.5-A.8 of the appendix. 
 All statistical analyses were conducted using SAS 9.4 (SAS Inc., Cary, NC). 
6.4. Results 
Of the 15,792 ARIC participants, 12,481 were included in the analysis after 
exclusions. The mean age of participants was 57 ± 5.7 at visit 2. Among these, 13.3% 
were anti-TPO positive, 2.3% had overt hypothyroidism, 4.7% subclinical 
hypothyroidism, 3.4% overt hyperthyroidism, 1.9% subclinical hyperthyroidism, 87.8% 
were euthyroid, and 7% were taking thyroid medication. Overall, participants with hypo- 
or hyperthyroidism had higher prevalences of risk factors for dementia compared to those 
with euthyroidism (Table 6.2). Participants with hypo- or hyperthyroidism were more 
likely to be women. Participants with hypothyroidism were less likely to be African 
American while participants with hyperthyroidism were more likely to be African 
American compared to those with euthyroidism. Those with hypothyroidism were less 
likely to be current tobacco smokers, less likely to have diabetes, and had higher mean 
84 
 
total cholesterol concentrations compared to participants in euthyroid or hyperthyroid 
categories. Participants with hyperthyroidism had higher HDL cholesterol and more 
prevalent CVD than those who were euthyroid or hypothyroid. Thyroid medication use 
was most common among participants with overt dysfunction.  
 A total of 2,235 dementia events occurred over a median follow-up of 21.9 
(maximum 27.7) years. Participants identified as anti-TPO antibody positive, a marker of 
AITD, did not have a statistically significant increased hazard of dementia compared to 
participants who were anti-TPO antibody negative even after multivariable adjustment 
[HR (95% CI): 0.90 (0.80, 1.03)] (Table 6.3). No association was found between overt 
hypothyroidism and dementia, compared to euthyroidism (Table 6.4). Subclinical 
hypothyroidism was associated with a 26% reduced hazard of dementia after full 
adjustment for covariates compared to participants with euthyroidism [HR (95% CI): 
0.74 (0.60, 0.92]. Overt hyperthyroidism was associated with a 40% increased hazard of 
dementia compared to participants with euthyroidism [HR (95% CI): 1.40 (1.02, 1.92)], 
while subclinical hyperthyroidism was not statistically significantly associated.  
 We also examined the association between categorical serum TSH and FT4 levels 
and dementia (Table 6.5). There was no association between continuous TSH level and 
dementia after multivariable adjustment including adjustment for serum FT4 levels. 
There was also no association between having TSH levels in the lowest 5% or highest 5% 
of categorical distribution and hazard of dementia compared to those in the middle 90% 
of TSH levels. A one standard deviation greater FT4 concentration was associated with a 
5% greater hazard of dementia after multivariable adjustment including adjustment for 
TSH [HR (95% CI): 1.05 (1.01, 1.09)]. Correspondingly, compared to participants in the 
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middle 90% of FT4 level, having serum FT4 in the highest 5% of the categorical 
distribution was associated with a 23% increased hazard of dementia after full adjustment 
[HR (95% CI): 1.23 (1.02, 1.48)].  In contrast, participants in the lowest 5% of FT4 level 
were not at increased hazard of dementia.  Using a restricted cubic spline model, we 
found levels of FT4 ≥ 1.1 ng/dL were positively, linearly associated with risk of dementia 
(Figure 6.1). In an ad hoc analysis, we tested a TSH*FT4 interaction term. The 
interaction term was not statistically significant. 
6.5. Discussion 
In this prospective cohort study of community-dwelling adults who were followed 
for 22 years from middle-age to older adulthood, subclinical hypothyroidism was 
associated with a reduced risk of dementia and overt hyperthyroidism with an increased 
risk of dementia, compared to euthyroid participants. We also found that neither 
continuous TSH nor categorical TSH were associated with increased risk of dementia. 
However, a standard deviation increase in FT4 was associated with an increased risk of 
dementia and those in the highest 5% of categorical FT4 were at increased risk. 
Our findings suggest that overt hyperthyroidism and elevated FT4 (the hormone 
used to diagnose hyperthyroidism) are associated with increased risk of dementia. These 
results are consistent with previous studies that found an association between elevated 
serum FT4 levels and dementia risk.282,283,286,287 We did not find an association between 
overt hypothyroidism and dementia nor TSH and dementia. This was inconsistent with 
the literature 278,283,288,289, which found a significant association between serum TSH (the 
hormone used to define hypothyroidism) and dementia. In addition, we found that 
subclinical hypothyroidism was associated with a reduced risk of dementia, an 
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association that we cannot explain. However, these results for clinical hypothyroidism 
may be related to lack of power. Despite ARIC’s large sample size, the vast majority of 
participants fell within the euthyroid category reducing the precision of our effect 
estimates. 
Strengths of this analysis include the long follow-up period, large sample size, as 
well as comprehensive ascertainment of dementia cases; however, some limitations 
warrant consideration. In our assessment of AITD, we only had one measure of 
autoimmunity, anti-TPO antibody levels. Yet, anti-TPO autoantibodies are found in over 
90% of patients with AITD and likely allowed us to capture the most AITD cases.297 
Another limitation is the change in thyroid hormone levels with aging that may have led 
to misclassification of subclinical hypothyroidism. As shown in our data and reported by 
others,285 in healthy adults ages 60 and older, average TSH levels rise with advancing age 
while FT4 concentrations remain fairly stable.298 Subclinical hypothyroidism is 
characterized by elevated TSH with FT4 in the normal range. Older ARIC participants 
may have had age-related changes in TSH levels that caused them to be misclassified as 
having euthyroidism when they had subclinical hypothyroidism. We were also only able 
to use one measure of thyroid hormone levels and could not adjust for age-related 
changes. However, these changes were likely modest and misclassification would have 
pushed effect estimates towards the null. Thus, misclassification does not likely explain 
the paradoxical inverse association between subclinical hypothyroidism and dementia, in 
the face of no association between overt hypothyroidism and dementia. In addition, our 
measure of AITD status should not be affected by age-related misclassification, and our 
analysis of thyroid hormone levels still allowed us to determine whether thyroid hormone 
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levels affect risk of incident dementia regardless of the cause of thyroid hormone 
dysfunction.  
Participants may have developed thyroid dysfunction over the follow-up period, 
and we tried to address this by adjusting for thyroid medication use at baseline as well as 
over follow-up. In these analyses, medication use was not associated with dementia and 
results did not change. Finally, while the ascertainment of dementia was extensive and 
included several different methods including adjudicated cases at clinic visits, 
surveillance of hospital and death certificate codes, and telephone interviews for 
cognitive status, there is still potential for either selection bias due to attrition or 
misclassification of cases. However, dementia cases were ascertained throughout the 
entire ARIC-NCS follow-up period, and our results do corroborate previous findings in 
the literature.  
Our analysis suggests that subclinical hypothyroidism may be associated with 
reduced risk of dementia, though the biological pathway is unclear and this potential 
association warrants further investigation. Additionally, our results show that overt 
hyperthyroidism may be a risk factor for dementia. By extrapolation from these 
observational data, it may be that effective treatment and management of thyroid 
hormone levels in overt hyperthyroidism could modestly reduce the risk of incident 
dementia.  
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6.6. Tables and Figures 
Table 6. 2. Baseline characteristics stratified by clinical categories of thyroid 
dysfunction, ARIC 1990-92 
 Hypothyroidism Eu-
thyroidism 
(n = 
10,956) 
Hyperthyroidism 
Risk Factors 
Overt 
(n = 281) 
Subclinical 
(n = 581) 
Subclinical 
(n = 429) 
Overt 
(n = 234) 
TSH > 5.1 
mIU/L; 
FT4 < 0.85 
ng/dL 
TSH > 5.1 
mIU/L; 
FT4 = 
0.85 - 1.4 
ng/dL 
TSH =  
0.56 - 5.1 
mIU/L; 
FT4 = 
0.85 - 1.4 
ng/dL 
TSH < 
0.56 
mIU/L; 
FT4 = 
0.85 - 1.4 
ng/dL 
TSH < 0.56 
mIU/L; 
FT4 > 1.4 
ng/dL 
Age, years 58.4 ± 5.4 58.4 ± 5.7 56.8 ± 5.7 56.5 ± 5.8 57.1 ± 5.8 
Men, % 22.8 33.4 45.9 33.6 19.7 
African 
American, % 12.8 11.0 25.1 41.5 23.1 
ApoE4 
carriers, % 29.2 29.6 29.9 27.3 28.2 
Basic 
Educationa, % 23.1 16.8 21.5 29.2 16.2 
Family 
Income < 
$16,000b, % 
24.2 21.3 25.2 34.3 22.2 
Current 
Alcohol 
Drinker, % 
48.8 58.7 57.1 49.2 56.0 
Current 
Tobacco 
Smoker, % 
13.9 12.9 22.3 29.6 25.2 
BMI, kg/m2 28.9 ± 5.7 27.7 ± 5.5 28.0 ± 5.4 27.6 ± 5.4 27.4 ± 5.4 
Hypertensionc, 
% 34.1 30.9 35.8 40.0 32.6 
Diabetesd, % 7.5 10.3 11.3 15.9 12.8 
HDL 
Cholesterol, 
mg/dL 
49.4 ± 16.6 49.7 ± 16.3 49.4 ± 16.8 52.8 ± 17.9 52.1 ± 15.7 
Total 
Cholesterol, 
mg/dL 
229.2 ± 
48.9 
214.3 ± 
41.2 
209.7 ± 
39.2 
208.1 ± 
38.0 199.5 ± 35.2 
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Prevalent 
CVDe, % 8.5 8.1 8.8 11.0 9.8 
Thyroid 
Medication 
Usef, % 
40.9 28.6 2.8 27.5 71.4 
TSH, mIU/L 26.3 ± 32.7 8.0 ± 4.4 2.0 ± 1.0 0.3 ± 0.2 0.1 ± 0.2 
FT4, ng/dL 0.7 ± 0.2 1.0 ± 0.1 1.1 ± 0.1 1.2 ± 0.1 1.8 ± 0.6 
Anti-TPO 
positive (> 34 
IU/L), %  
79.4 51.1 9.3 13.8 27.4 
SD: Standard deviation 
a Based on self-report of  some high school education or less at visit 1 (1987-89) 
b Based on self-report of  income at visit 1 (1987-89) 
c Defined as diastolic blood pressure > 90 mm Hg, systolic blood pressure > 140 mm Hg, 
or use of hypertensive medication 
d Defined as non-fasting blood glucose > 200 mg/dL, fasting blood glucose > 126 mg/dL, 
self-report of diabetes, or reporting taking medication for diabetes or high blood sugar  
e Defined as prevalent stroke, coronary heart disease, myocardial infarction, or atrial 
fibrillation at visit 2 
f Participants who reported thyroid medication use at baseline  
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Table 6. 3. Hazard ratios (95% CI) of dementia by anti-TPO positivity status, ARIC 
1990-2017  
 
Anti-TPO Negative 
≤ 34 IU/L 
Anti-TPO Positive 
>34 IU/L 
n total = 10,821 n total = 1,660 
n events = 1,932 n events = 303 
Model 1 HR 1  (ref) 
0.92  
(0.82, 1.04) 
Model 2 HR 1  (ref) 
0.93 
(0.82, 1.05) 
Model 3 HR 1 (ref) 
0.90 
(0.80, 1.03) 
Abbreviation: HR: Hazard ratio; CI: Confidence interval 
Model 1: age, sex, race-center, ApoE4, income, and education  
Model 2: Model 1 + BMI, smoking status, hypertension, diabetes, drinking status, HDL 
cholesterol, and total cholesterol 
Model 3: Model 2 + CVD and baseline thyroid medication 
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Table 6. 4. Hazard ratios (95% CI) of dementia by clinical categories of thyroid 
dysfunction, ARIC 1990-2017  
 
Hypothyroidism Eu-
thyroidism 
Hyperthyroidism 
Overt Subclinical Subclinical  Overt 
TSH > 5.1 
mIU/L; 
FT4 < 0.85 
ng/dL 
TSH > 5.1 
mIU/L; 
FT4 = 
0.85 - 1.4 
ng/dL 
TSH =  
0.56 - 5.1 
mIU/L; 
FT4 = 
0.85 - 1.4 
ng/dL 
TSH < 0.56 
mIU/L; 
FT4 = 
0.85 - 1.4 
ng/dL 
TSH < 0.56 
mIU/L; 
FT4 > 1.4 
ng/dL 
n total = 
281 
n total = 
581 
n total = 
10,956 n total = 429 
n total = 
234 
n events = 
60 
n events = 
98 
n events = 
1,952 
n events = 
74 
n events = 
51 
Model 1 
HR 
1.03 
(0.80, 1.33) 
0.78* 
(0.64, 0.96) 
1  
(Ref) 
1.07 
(0.85, 1.35) 
1.51* 
(1.14, 1.99) 
Model 2 
HR 
1.01 
(0.78, 1.31) 
0.76* 
(0.61, 0.93) 
1  
(Ref) 
1.03 
(0.81, 1.31) 
1.49* 
(1.12, 1.98) 
Model 3 
HR 
0.96 
(0.73, 1.26) 
0.74* 
(0.60, 0.92) 
1  
(Ref) 
1.01 
(0.79, 1.29) 
1.40* 
(1.02, 1.92) 
Abbreviation: HR: Hazard ratio; CI: Confidence interval 
*P-value < 0.05 
Model 1: age, sex, race-center, ApoE4, income, and education 
Model 2: Model 1 + BMI, smoking status, hypertension, diabetes, drinking status, HDL 
cholesterol, and total cholesterol. 
Model 3: Model 2 + CVD and baseline thyroid medication 
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Table 6. 5. Hazard ratios (95% CI) of dementia by categorical distribution of thyroid 
hormone level, ARIC 1990-2017 
Thyroid Stimulating Hormone 
 
Lowest 5% 
≤ 0.54 mIU/L 
Middle 90% 
0.55 – 5.97 
mIU/L 
Highest 5% 
≥ 5.98 mIU/L 
TSH per 6.35 
mIU/L 
n total = 626 n total =11,226 n total = 629 n total = 12,481 
n events = 116 n events = 1,998 n events = 121 
n events = 
2,235 
Model 1 HR 1.24* (1.03, 1.50) 
1 
(ref) 
0.93 
(0.77, 1.12) 
1.03 
(0.98, 1.07) 
Model 2 HR 1.13 (0.92, 1.39) 
1 
(ref) 
0.94 
(0.77, 1.14) 
1.03 
(0.98, 1.07) 
Model 3 HR 1.09 (0.87, 1.36) 
1 
(ref) 
0.90 
(0.73, 1.11) 
1.02 
(0.97, 1.07) 
Free T4 
 
Lowest 5% 
≤ 0.89 ng/dL 
Middle 90% 
0.90 – 1.35 
ng/dL 
Highest 5% 
≥ 1.36 ng/dL 
FT4 per SD 
(0.19 ng/dL) 
n = 628 n = 11,170 n = 683 n = 12,481 
n events = 123 n events = 1,981 n events = 131 
n events = 
2,235 
Model 1 HR 0.96 (0.79, 1.18) 
1 
(ref) 
1.30* 
(1.08, 1.55) 
1.06* 
(1.02, 1.09) 
Model 2 HR 0.96 (0.78, 1.17) 
1 
(ref) 
1.26* 
(1.05, 1.51) 
1.05* 
(1.01, 1.09) 
Model 3 HR 0.95 (0.77, 1.16) 
1 
(ref) 
1.23* 
(1.02, 1.48) 
1.05* 
(1.01, 1.09) 
Abbreviation: HR: Hazard ratio; CI: Confidence interval 
*P-value < 0.05 
Model 1: age, sex, race-center, ApoE4, income, education, and TSH or FT4  
Model 2: Model 1 + BMI, smoking status, hypertension, diabetes, drinking status, HDL 
cholesterol, and total cholesterol. 
Model 3: Model 2 + prevalent CVD and baseline thyroid medication use 
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Figure 6. 1. Age, sex race-center, ApoE4, income, education, and TSH adjusted hazard 
ratio (95% CI) of incident dementia in relation to serum FT4*, ARIC, 1990-2017 
 
*Analyzed using restricted cubic splines with knots at the 5th (0.90 ng/dL), 50th (1.11 
ng/dL), and 95th (1.35 ng/dL) percentiles of the FT4 distribution. FT4 hormone levels 
were truncated at the 1st (0.71 ng/dL) and 99th (1.61 ng/dL) centiles to minimize the 
influence of extreme values. 
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CHAPTER 7. MANUSCRIPT 3: MIGRAINES AND RISK OF DEMENTIA AND 
MCI 
7.1 Overview 
Background 
Migraine headache is a common neurological disorder that is associated with 
white matter hyperintensities. White matter disease is associated with cognitive decline in 
the general population, but the relation has not been studied in the context of migraine. 
Our aim was to use the Atherosclerosis Risk in Communities (ARIC) Neurocognitive 
Study (1993-2017) to determine whether migraine is associated with incident dementia 
and mild cognitive impairment (MCI), particularly of cerebrovascular disease etiology, 
and whether this association varies by sex.  
Methods 
Lifetime history of migraine and severe non-migraine headache symptoms were 
ascertained via questionnaire. Adjudicated cases of dementia and MCI were identified 
using cognitive tests, neuropsychological examinations, and clinician review of suspected 
cases. Cerebrovascular disease etiology was identified in brain imaging. Total dementia 
cases were identified using adjudicated dementia cases, annual and semi-annual 
telephone interviews for cognitive status, and surveillance of hospital and death 
certificate codes. Relative risk regression with inverse probability of attrition weighting 
was used to assess the risk of adjudicated dementia and MCI, and Cox regression was 
used to assess hazard of total dementia.  
Results 
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Analysis included 12,501 white and African American participants ages 51-70, of 
whom 1,398 reported migraine and 1,244 reported severe non-migraine headache 
symptoms at baseline. There was no association between history of migraine or severe 
non-migraine headache symptoms and incidence of adjudicated dementia and MCI 
[Migraine RR (95% CI): 1.00 (0.89, 1.14)] nor total dementia [Migraine HR (95% CI): 
1.04 (0.91, 1.20)]. The lack of association did not differ by sex nor were migraine or 
severe non-migraine headache symptoms associated with incident cerebrovascular 
disease-related dementia and MCI.   
Conclusion 
Despite reported evidence of brain abnormalities in migraineurs associated with 
cognitive changes in older adult populations, there was no association between history of 
migraine symptoms and incident dementia and MCI in this prospective cohort followed 
for 25 years. 
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7.2. Background 
 Migraine headache is a complex neurological disorder characterized by throbbing, 
severe, and typically unilateral pain in the head.299 Among Americans ages 12 and older, 
prevalence is about 6.5% in men and 18.2% in women and has remained stable over 
time.300,301 Migraine prevalence peaks between the ages of 30 and 39 for both men and 
women before falling to reach its lowest prevalence in those 60 and older.302 For both 
sexes, prevalence is significantly higher in whites than African Americans and among 
those with low versus high income.302 It is a heritable disorder with relatives of 
migraineurs at three times the risk compared to those without relatives with migraines.303  
Approximately 64% of migraines are without aura, 18% with aura, and some 
individuals experience both.299 Migraine is associated with autonomic, sensory, affective, 
and cognitive symptoms including nausea, vomiting, sensitivity to light, sound, and 
movement, depression and irritability, attention deficit, and transient amnesia.299,304 This 
constellation of early migraine symptoms, also known as prodromes, can vary 
substantially between individuals.  
 Prodromes can precede migraine headache by several hours and are explained by 
two main hypotheses.304 The first theorizes that hypothalamic neurons respond to changes 
in brain homeostasis by activating meningeal nociceptors that alter the balance of 
parasympathetic and sympathetic activity in the meninges toward predominance of 
parasympathetic activity.304 The second theory proposes that hypothalamic and brainstem 
neurons that respond to brain homeostasis lower the threshold for transmission of 
nociceptive trigeminovascular signals from the thalamus to the cortex.304 This can alter 
the amount of brain activity required to manage emotional and physiological stress, 
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making migraineurs more susceptible to external and internal stressors.304 Both theories 
identify neuronal hyper-excitability as well as alterations to the brain structure and 
function, resultant from the repetitive state of headache, as essential features of migraine 
progression.304-306 
 There is an important distinction between migraine with and without aura, and 
evidence suggests the two subtypes of migraine may be separate disorders.306 Aura is 
characterized by fully reversible neurologic dysfunction related to visual, sensory, 
speech/language, motor, brainstem, or retinal symptoms that proceed or accompany 
headache.307 Onset is usually gradual with a duration of 5-60 minutes, and visual aura is 
the most commonly reported with prevalence estimates as high as 99%.307 Aura is distinct 
from prodromes and caused by cortical spreading depression (CSD).307 Evidence 
suggests that CSD involves a wave of hyper-excitation followed by suppression of 
cortical neurons and glia.304,306 This process is associated with disruption of ionic flow 
and leads to an increase and subsequent decrease of cerebral blood flow.307 As with 
prodromes, it is unknown what triggers CSD associated with aura.307 
 The mechanisms of the headache stage of migraine are better characterized than 
prodromes and aura. The initial “vascular hypothesis” proposed that migraines were a 
vasospastic disorder that started with meningeal blood vessel constriction followed by 
dilation, activating the surrounding trigeminal sensory nerves and causing pain.308,309 
However, vasodilation alone does not fully explain prodromes that can accompany 
headache, and current hypotheses focus primarily on neural activation with vascular 
changes as a secondary factor.308 It is hypothesized that migraine headache is caused by 
activation of the trigeminovascular system via dilation of meningeal blood vessels that 
98 
 
mechanically activate surrounding trigeminal sensory nerve fibers.306,310 Activation of 
these fibers triggers release of the vasoactive neurotransmitter calcitonin gene-related 
peptide (CGRP).306,310 Signals spread via CGRP to the pain matrix of the brain, the 
thalamus, followed by the brainstem and spinal cord regions causing headache.306,310 As 
migraine progresses, areas of the brain that receive pain impulses may become sensitized, 
leading to perpetuation of CGRP release, worsening of pain, and increased sensitivity to 
stimuli.306,310,311 Concentration of CGRP is elevated in migraine patients, and the 
neurotransmitter has been a target for intervention using selective CGRP receptor 
antagonists.310,311 
 While current hypotheses deemphasize the importance of vasodilation in 
migraine, there is still a clear vascular component, which has led researchers to test the 
connection between migraine, stroke, and cognitive decline. Several studies have found 
an association between migraine and ischemic stroke with a pooled relative risk of 1.7 
(95% CI: 1.3, 2.4); this association was significant in women [RR (95% CI): 2.1 (1.1, 
3.8)], but not in men [RR (95% CI): 1.4 (0.9, 2.1)].312 An ARIC study found a history of 
migraine symptoms was cross-sectionally associated with cerebral white matter 
hyperintensities.313 In addition, a recent review concluded that history of migraine was 
associated with increased odds of white matter abnormalities, subclinical infarct-like 
lesions, and volumetric changes in the brain.314 Stroke, white matter hyperintensities, 
silent infarcts, and volumetric changes are associated with increased risk of cognitive 
impairment, suggesting migraine may be a risk factor for cognitive decline and 
dementia.315  
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Accumulating evidence indicates that many cases of dementia have mixed 
pathologies, with a combination of AD and CeVD being the most common.316,317 It is 
plausible that migraine could contribute not only to CeVD-specific dementia cases, but 
also more broadly to risk of dementia and mild cognitive impairment (MCI), a clinically 
significant pre-dementia state.315,318 Few longitudinal studies have looked at migraine and 
risk of developing dementia and MCI (Table A.9).319-322 Of the studies that have assessed 
this relationship, results have been mixed and most sample sizes have been small. 
Further, to our knowledge, no studies in U.S. community-based cohorts have assessed 
this association.  
 Our first aim was to evaluate the association between migraine status based on 
self-reported headache symptoms with risk of dementia and MCI. We hypothesized that 
ARIC participants who reported historical symptoms of migraine would be at increased 
risk of dementia and MCI. We also hypothesized that participants who were classified as 
having a history of migraine with aura would be at increased risk of dementia compared 
to those who experienced migraine without aura, severe headache, or no headache. Our 
second aim was to evaluate the association between self-reported history of migraine 
symptoms with risk of dementia and MCI with cerebrovascular disease etiology and non-
CeVD-related etiology, separately. We hypothesized that the association between 
migraine and dementia would be stronger in those with dementia and MCI with a CeVD 
etiology compared to non-CeVD etiology. Our third aim was to determine whether there 
was effect modification on the association between migraine and dementia and MCI by 
sex. We hypothesized that the association between migraine and dementia would be 
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stronger in women compared to men based previous study findings and the higher 
prevalence of migraines in women than men. 
7.3. Methods  
 We analyzed the association between migraine and dementia and MCI in ARIC-
NCS using a prospective cohort study design with a baseline at visit 3 (1993-95) through 
visit 6 (2016-17). Participants were excluded if they did not attend visit 3 (n = 2,886), 
were missing migraine status based on self-reported headache symptoms (n = 57), had 
prevalent stroke (n = 245), prevalent dementia (identified via ICD codes) (n = 6), or were 
non-white or African American or were African American from Maryland or Minnesota 
(n = 103) for a final analytic sample of 12,495 participants.  
 Migraine status was assessed at visit 3 via questionnaire of self-reported headache 
symptoms adapted from the International Headache Society diagnostic criteria. Migraine 
was defined as: 1) headache lasting 4 or more hours, 2) headache with throbbing, 
pounding, or pulsating pain, or that was unilateral, 3) symptoms of nausea, vomiting, or 
sensitivity to light or sound, and 4) one or more years with history of headaches.313 Those 
who reported headache lasting four or more hours, but did not meet all the other criteria 
for migraine were defined as suffering from severe non-migraine headache, and 
participants who denied having a headache lasting 4 or more hours were classified as 
having no headache.318 Participants meeting the definition of migraine were defined as 
having aura if they reported the occurrence of visual aura (e.g. spots, jagged lines, 
etc.).318  
 Covariates included age, sex, race-center (MS-blacks, NC-whites, NC-blacks, 
MN-whites, and MD-whites), ApoE4, income, and education from visit 1 and BMI, 
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smoking status, hypertension, diabetes, prevalent CHD, drinking status, HDL cholesterol, 
and total cholesterol from visit 3. BMI was calculated from weight and height 
measurements taken at the visit. Hypertension was defined as having a systolic blood 
pressure > 140 mm Hg, diastolic blood pressure > 90 mm Hg, or self-report of 
antihypertensive medication use. Diabetes was defined as non-fasting glucose ≥ 200 
mg/dL, fasting blood glucose ≥ 126 mg/dL, self-report of diabetes diagnosis from a 
physician, or report of taking medication for diabetes or high blood sugar. 
Dementia and MCI cases were identified from ARIC-NCS clinic examinations 
conducted at visits 5 and 6, surveillance of hospital and death certificate codes, and 
annual and semi-annual telephone-based cognitive assessments. Methods are described in 
detail in Chapter 4. Separate analyses were run using two criteria for dementia and MCI 
cases. The first definition included all incident dementia cases available in ARIC between 
visits 3 and 6. This included cases identified using surveillance of hospital and death 
records, annual and semi-annual modified telephone interviews for cognitive status 
(TICSm), and adjudicated dementia identified in ARIC-NCS. The second definition 
included only adjudicated dementia and MCI cases identified in ARIC-NCS at visits 5 
and 6. Further, from brain MRI data at visit 5, adjudicated dementia and MCI cases were 
classified as being CeVD-related if primary or secondary CeVD etiology was identified. 
Dementia surveillance is believed to be relatively complete, but because analysis of MCI 
required attendance at visits 5 or 6, there was likely informative censoring of participants 
over the follow-up period.83 To account for this potential selection bias, we used inverse 
probability of attrition weights (IPAW) in our analyses of adjudicated cases.83,255   
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 Statistical Analysis 
Poisson regression was used to estimate incidence of dementia stratified by 
headache subtype (migraine, severe non-migraine headache, no headache) and sex. We 
then evaluated the association between self-reported history of migraine symptoms with 
risk of dementia and MCI (Aim 1). Cox regression was used to calculate hazard ratios of 
dementia stratified by headache subtype between visits 3 and 6 with no headache as the 
reference. Relative risk regression with a Poisson distribution and log link was used to 
assess the association between migraine and adjudicated dementia or MCI using IPAW to 
account for informative censoring caused by death or failure to attend visits 5 or 6 
(methods described in detail elsewhere).255 The association of migraine with aura and 
dementia or MCI was assessed by repeating the Cox regression and relative risk 
regression models using an added “migraine with aura” headache subtype.  
To address aim 2, we evaluated the association between self-reported history of 
migraine symptoms with risk of dementia and MCI with primary or secondary CeVD 
etiology compared to dementia cases without CeVD etiology. Etiologic data are available 
for dementia and MCI cases only at visit 5, so analysis was restricted to individuals seen 
at visit 5. Relative risk regression with IPAW was used to assess the association between 
migraine and CeVD-related and non-CeVD-related dementia and MCI in separate 
models.  
Finally, to determine whether there is effect modification on the association 
between migraine and dementia and MCI by sex (Aim 3), a sex by migraine 
multiplicative interaction term was tested in the models. Cox regression and relative risk 
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regression were used to assess hazard and risk of dementia and MCI, respectively.  For 
both analyses, sex-specific models are presented.  
A hazard ratio of approximately 1.4 and a relative risk ratio of 1.6 or greater 
would have been needed to detect an effect with 80% power and a type I error rate of 0.5.  
7.4 Results 
 After exclusions, analysis included an analytic sample of 12,495 participants with 
a mean age of 60 and median follow-up time of 21 years. Participants who reported 
experiencing migraine symptoms were more likely to be younger, white, female, and had 
higher HDL and total cholesterol than those who reported no headache symptoms or 
severe non-migraine headache symptoms (Table 7.1). In addition, migraineurs were less 
likely to have hypertension, diabetes, or be a current alcohol drinker.  There was no 
statistically significant difference in the overall incidence of dementia between those who 
experienced migraine symptoms compared to those who experienced severe non-
migraine headaches or no headaches between visits 3 and 6 (Figure 7.1). 
 Those who experienced migraine symptoms at baseline had neither a significantly 
increased hazard of incident dementia [HR (95% CI): 1.04 (0.91, 1.20)] nor a 
significantly increased risk of adjudicated dementia or MCI [RR (95% CI): 1.00 (0.89, 
1.14)], compared to those with no headache (Table 7.2). There was no significant 
association between migraine with aura and incident dementia or with adjudicated 
dementia or MCI. There also was no association for severe non-migraine headache 
compared to no headache, and relationships remained insignificant even after full 
adjustment for risk factors. 
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As shown in Table 7.3, history of migraine or severe non-migraine headache 
symptoms was not significantly associated with increased risk of adjudicated dementia 
and MCI with or without cerebrovascular disease etiology even after full adjustment. 
Finally, the sex*migraine status interaction term was not statistically significant in any 
model, indicating that the associations between migraine status and risk of dementia and 
MCI were similarly null for men and women (Table 7.4).  
7.5. Discussion 
 Using a large population-based prospective study, we found no association 
between history of migraine symptoms and risk of dementia or MCI. This lack of 
association was found in cerebrovascular and non-cerebrovascular etiologies and in both 
men and women. While migraine is associated with cerebrovascular lesions, migraine-
related lesions are reported to be stable over time and may not contribute to dementia 
pathophysiology later in life.313 This analysis is an important contribution to the literature 
because few studies have assessed the association between migraine and dementia and 
MCI in a large, American cohort with over 25 years of follow-up. 
There are several limitations to our analysis. Despite the size of our cohort, power 
was somewhat limited. A hazard ratio of approximately 1.4 and a relative risk ratio of 1.6 
would have been needed to detect an effect with an alpha of 0.05 and 80% power. In 
addition, there was potential selection bias due to attrition and misclassification of the 
dementia and MCI cases that were not examined directly. However, IPAW was used to 
correct for selection bias in analysis of adjudicated dementia and MCI cases, and ARIC 
used a variety of strategies to prevent attrition and identify possible dementia cases 
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among participants who did not attend all clinic visits including surveillance of hospital 
and death records as well as follow-up telephone interviews.  
Another limitation was potential misclassification of migraine status due to 
reliance on report of headache symptoms over participants’ lifetimes measured via self-
report when participants ranged in age from 51-70.302  Two population-based studies 
using questionnaires adapted from the International Headache Society diagnostic criteria, 
from which the ARIC questionnaire was derived, confirmed the validity and reliability of 
using abbreviated diagnostic criteria to accurately identify migraineurs estimating 
Cohen’s kappa coefficients ranging from 0.43-0.68.323,324  Further, the symptoms 
associated with migraine, including unilateral, severe pain, prodromes, and aura, would 
not likely be forgotten and should be easily distinguishable from a severe non-migraine 
headache in most cases. By asking participants about their migraine history after 
prevalence peaked in young adulthood and middle age, it is less likely cases were missed. 
Misclassification of migraine status would have tended to mask any associations with 
dementia. Because migraine in ARIC is associated with increased stroke risk, 325 as in 
other studies, 312,326,327 the validity of the ARIC migraine classification is likely adequate.  
Finally, we were unable to account for age of onset or duration of migraines.  
In summary, we found no association between history of migraine headache and 
incident dementia or MCI in ARIC.  While there is evidence that migraine is associated 
with brain alterations that have been linked to cognitive changes, these alterations may 
not be clinically meaningful or they may resemble white matter hyperintensities 
associated with vascular disease, but have a different underlying pathophysiologic 
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process.313-315 Additional research with a larger sample size and more extensive migraine 
history is warranted.  
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7.6 Tables and Figures  
Table 7. 1. Baseline participant characteristics stratified by migraine status, ARIC, 1993-
1995 
Characteristic No Headache 
Severe Non-
migraine 
Headache 
Migraine 
 n total = 9,855 n total = 1,243 n total = 1,397 
Age, years 60.4 ± 5.7 58.7 ± 5.5 58.3 ± 5.5 
African American, % 24.7 15.3 14.5 
Male, % 48.2 36.0 22.1 
ApoE4 carriers, % 29.3 27.0 29.3 
Basic Educationa, % 20.8 15.5 18.5 
Family Income < $16,000b, 
% 23.9 19.2 23.4 
Current Alcohol Drinker, % 52.5 53.9 49.5 
Current Tobacco Smoker, % 18.0 16.4 16.7 
BMI, kg/m2 28.6 ± 5.6 27.9 ± 5.3 28.4 ± 5.9 
Hypertensionc, % 41.7 36.1 35.9 
Diabetesd, % 15.9 12.4 11.6 
HDL Cholesterol, mg/dL 51.7 ± 18.2 53.9 ± 18.4 55.1 ± 18.3 
Total Cholesterol, mg/dL 207.0 ± 37.4 207.0 ± 37.9 211.6 ± 39.3 
Mean ± Standard Deviation  
a Based on self-report of some high school education or less at visit 1  
b Based on self-report of income at visit 1 (1987-89) 
c Defined as diastolic blood pressure > 90 mm Hg, systolic blood pressure > 140 mm Hg, 
or use of hypertensive medication 
d Defined as non-fasting blood glucose > 200 mg/dL, fasting blood glucose > 126 mg/dL, 
self-report of diabetes, or reporting taking medication for diabetes or high blood sugar  
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Figure 7. 1. Incidence rates of dementia adjusted for age and stratified by baseline 
headache subtype and sex, ARIC, 1993-2017  
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Women 8.5 7.8 9.0
Men 9.0 9.3 7.9
0.0
1.0
2.0
3.0
4.0
5.0
6.0
7.0
8.0
9.0
10.0
In
ci
de
nc
e 
ra
te
s o
f d
em
en
tia
 p
er
 1
00
0 
pe
rs
on
 y
ea
rs
109 
 
Table 7. 2. Hazard ratios (95% CI) and relative risks (95% CI) of dementia and MCI in 
relation to baseline headache status, ARIC 1993-2017 
Dementia only 
 
No Headache 
Severe Non-
Migraine 
Headache 
Migraine 
n total = 9,855 n total = 1,243 n total = 1,397 
n events = 
1,821 n events = 196 n events = 233 
Model 1 HR 1 (Ref) 
1.00 
(0.86, 1.16) 
1.02 
(0.89, 1.17) 
Model 2 HR 1 (Ref) 
1.00 
(0.87, 1.17) 
1.04 
(0.91, 1.20) 
 
No Headache 
Severe Non-
Migraine 
Headache 
Migraine 
without Aura 
Migraine with 
Aura 
n total = 9,855 n total = 1,243 n total = 992 n total = 405 
n events = 
1,821 n events = 196 n events = 165 n events = 68 
Model 1 HR 1 (Ref) 
1.00 
(0.86, 1.16) 
0.99 
(0.84, 1.16) 
1.11 
(0.87, 1.42) 
Model 2 HR 1 (Ref) 
1.00 
(0.87, 1.17) 
1.01 
(0.86, 1.19) 
1.12 
(0.88, 1.43) 
MCI and Dementia at visits 5 and 6 
 
No Headache 
Severe Non-
Migraine 
Headache 
Migraine 
n total = 8,517 n total = 1,104 n total = 1,242 
n events = 
1,760 n events = 236 n events = 261 
Model 1 RR 1 (Ref) 
0.96 
(0.83, 1.10) 
0.99 
(0.87, 1.12) 
Model 2 RR 1 (Ref) 
0.96 
(0.83, 1.11) 
1.00 
(0.89, 1.14) 
 
No Headache 
Severe Non-
Migraine 
Headache 
Migraine 
without Aura 
Migraine with 
Aura 
n total = 8,517 n total = 1,104 n total = 879 n total = 363 
n events = 
1,760 n events = 236 n events = 191 n events = 70 
Model 1 RR 1 0.96 0.97 1.03 
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(Ref) (0.83, 1.11) (0.84, 1.13) (0.82, 1.29) 
Model 2 RR 1 (Ref) 
0.96 
(0.83, 1.11) 
0.98 
(0.85, 1.13) 
1.06 
(0.85, 1.34) 
Abbreviations: HR: Hazard ratio; RR: Risk ratio; CI: Confidence interval 
Model 1: age, sex, race-center, ApoE4, income, and education 
Model 2: Model 1 + BMI, smoking status, hypertension, diabetes, prevalent CHD, 
drinking status, HDL cholesterol, and total cholesterol. 
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Table 7. 3. Relative risks (95% CI) of dementia and MCI at visits 5 and 6 by etiology in 
relation to baseline headache status, ARIC 1993-2017 
Cerebrovascular Disease Etiology 
 
No Headache Severe Non-Migraine Headache Migraine 
n total = 7,383 n total = 953 n total = 1,068 
n events = 441 n events = 40 n events = 57 
Model 1 RR 1 (Ref) 
1.34 
(0.95, 1.88) 
1.05 
(0.79, 1.41) 
Model 2 RR 1 (Ref) 
1.36 
(0.97, 1.91) 
1.09 
(0.82, 1.46) 
Non-Cerebrovascular Disease Etiology 
 
No Headache Severe Non-Migraine Headache Migraine 
n total = 8,076 n total = 1,064 n total = 1,185 
n events = 1,134 n events = 151 n events = 174 
Model 1 RR 1 (Ref) 
1.05 
(0.88, 1.24) 
0.94 
(0.79, 1.13) 
Model 2 RR 1 (Ref)) 
1.06 
(0.90, 1.25) 
0.97 
(0.81, 1.16) 
Abbreviations: RR: Risk ratio; CI: Confidence interval 
* Statistically significant (p-value < 0.05) 
Model 1: age, sex, race-center, ApoE4, income, and education 
Model 2: Model 1 + BMI, smoking status, hypertension, diabetes, prevalent CHD, 
drinking status, HDL cholesterol, and total cholesterol. 
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Table 7. 4. Hazard ratios (95% CI) and relative risks (95% CI) of dementia and MCI in 
relation to baseline headache status and sex, ARIC 1993-2017 
 Sex-specific Dementia only 
 
Women 
(n = 6,988) 
Men 
(n = 5,507) 
No 
Headache 
Severe 
Non-
Migraine 
Headache  
Migraine  No Headache 
Severe 
Non-
Migraine 
Headache  
Migraine 
n total = 
5,105 
n total = 
795 
n total = 
1,088  
n total = 
4,750 
n total = 
375 
n total = 
309 
n events = 
1,012 
n events 
= 123 
n events 
= 190 
n events = 
809 
n events = 
73 
n events = 
43 
Model 
1 HR 
1 
(Ref) 
0.96 
(0.80, 
1.16) 
1.09 
(0.93, 
1.28) 
1 
(Ref) 
1.09 
(0.85, 
1.38) 
0.82 
(0.60, 
1.11) 
Model 
2 HR 
1 
(Ref) 
0.97 
(0.80, 
1.17) 
1.13 
(0.96, 
1.32) 
1 
(Ref) 
1.09 
(0.85, 
1.39) 
0.79 
(0.58, 
1.08) 
 Sex-specific MCI and Dementia at visits 5 and 6 
 
Women 
(n = 6,020) 
Men 
(n = 4,843) 
No 
Headache 
Severe 
Non-
Migraine 
Headache  
Migraine  No Headache 
Severe 
Non-
Migraine 
Headache  
Migraine 
n total = 
4,350 
n total = 
706 
n total = 
964 
n total = 
4,167 
n total = 
398 
n total = 
278 
n events = 
900 
n events 
= 145  
n events 
= 193 
n events = 
860 
n events = 
91 
n events = 
68 
Model 
1 RR 
1 
(Ref) 
0.99 
(0.83, 
1.17) 
0.99 
(0.85, 
1.15) 
1 
(Ref) 
0.88 
(0.69, 
1.12) 
0.90 
(0.71, 
1.13) 
Model 
2 RR 
1 
(Ref) 
0.99 
(0.84, 
1.17) 
1.00 
(0.86, 
1.16) 
1 
(Ref) 
0.88 
(0.69, 
1.12) 
0.90 
(0.72, 
1.13) 
Abbreviations: HR: Hazard ratio; RR: Risk ratio; CI: Confidence interval 
Model 1: age, race-center, ApoE4, income, and education 
Model 2: Model 1 + BMI, smoking status, hypertension, diabetes, prevalent CHD, 
drinking status, HDL cholesterol, and total cholesterol. 
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CHAPTER 8. CONCLUSIONS 
 The public health burden of dementia and MCI is increasing as the population 
ages. The objective of this dissertation was to describe the etiology and epidemiology of 
dementia and MCI, characterize major demographic, genetic, vascular, and behavioral 
risk factors, and examine three novel risk factors in early- and mid-life that may influence 
late-life risk. Using the ARIC study cohort, we assessed life-course SES, thyroid 
dysfunction, and lifetime history of migraine symptoms as three novel risk factors for 
dementia and MCI using a prospective cohort study design and epidemiologic methods.  
 In manuscript 1, we examined the association between LC-SES at the individual- 
and neighborhood-levels and risk of dementia and MCI using a LC-SES summary score. 
SES has been studied in relation to cognitive impairment extensively, in part, due to the 
relation between SES and cognitive reserve. However, few studies have assessed this 
association using SES over the life-course, from childhood through middle/older 
adulthood, and at the individual and neighborhood level. After stratifying by life epoch 
(childhood, young adulthood, and middle/older adulthood) and SES tertile (low, middle, 
high), we found that incidence of dementia was significantly lower among those in the 
highest SES tertile vs. the lowest during young adulthood and middle/older adulthood. 
This association was similar, but not statistically significant during childhood. 
Additionally, a standard deviation (SD) increase in individual-level LC-SES score was 
associated with moderately lower incidence of dementia in both whites [HR (95% CI): 
0.86 (0.81, 0.92)] and African Americans [HR (95% CI): 0.79 (0.71, 0.87)]. When 
education was taken out of the individual LC-SES score and adjusted for separately, a SD 
increase in individual LC-SES score was still associated with lower dementia risk in 
114 
 
whites [HR (95% CI): 0.90 (0.84, 0.97)] and African Americans [HR (95% CI): 0.85 
(0.76, 0.96)] though associations were attenuated. We found no association between 
cumulative neighborhood-level LC-SES and incident dementia independent of 
individual-level LC-SES. Results were similar in our analysis of adjudicated dementia 
and MCI. 
 In manuscript 2, we assessed the association between mid-life thyroid dysfunction 
and dementia and MCI. We found no association between autoimmune thyroid disease as 
measured via anti-TPO antibodies and risk of dementia. Subclinical hypothyroidism was 
associated with a reduced risk of dementia [HR (95% CI): 0.74 (0.60, 0.92] and overt 
hyperthyroidism with an increased risk of dementia [HR (95% CI): 1.40 (1.02, 1.92)] 
compared to euthyroid participants. Neither continuous nor categorical TSH levels were 
associated with increased risk of dementia. However, a SD increase in FT4 was 
associated with an increased risk of dementia, and those in the highest 5% of categorical 
FT4 were at increased risk of incident dementia. Our findings suggest that subclinical 
hypothyroidism is associated with reduced risk of dementia though the biological 
pathway is unclear and warrants further investigation. In addition, overt hyperthyroidism 
may be a risk factor for dementia, particularly at very high levels of FT4. We analyzed 
the association between thyroid dysfunction and adjudicated dementia and MCI and 
found no associations. 
 Finally, in manuscript 3, we assessed the association between lifetime history of 
migraine symptoms and risk of dementia and MCI. Brain abnormalities associated with 
cognitive impairment in older adults, including white matter hyperintensities and 
volumetric changes, have been identified in migraineurs. History of migraine is also 
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associated with increased risk of ischemic stroke. However, we found no association 
between lifetime history of migraine symptoms or severe-non migraine headache and risk 
of dementia and MCI. There was no association between migraine and dementia and MCI 
with cerebrovascular etiology nor an interaction between migraine and sex. While 
migraineurs have increased odds of brain alterations linked to cognitive impairment, 
these changes may not be clinically meaningful despite resembling vascular pathology. 
 Dementia and MCI are complex conditions that represent several different 
etiologies and phenotypes. Outside of disease-causing gene mutations, the cause of 
dementia and MCI cannot be isolated to a single risk factor. This dissertation has focused 
on identifying novel early- and mid-life risk factors for dementia and MCI. Our findings 
suggest that life course socioeconomic factors have a moderate influence on late-life 
dementia risk and that both economic and educational aspects of SES contribute to that 
risk. Further, thyroid dysfunction, particularly overt hyperthyroidism may moderately 
increase risk of dementia. Lifetime history of migraine symptoms were not associated 
with dementia or MCI, though migraine has been previously associated with brain 
abnormalities detected by brain imaging.  
 Future research should continue to examine risk factors for dementia and MCI, 
particularly in large, diverse cohorts. In addition, results from observational studies of 
risk factors should be used to develop primary prevention studies that can attempt to 
prevent dementia and MCI outcomes through risk factor modification.   
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APPENDIX 
Life Course SES (Chapter 5) 
Table A. 1. Literature review of the association between socioeconomic status and cognitive impairment 
Citation Study Design Population Exposure Follow-up Time Outcome(s) Results 
Wu, 2015241 
Systematic-
Review 
(n studies = 15) 
Participants from 
US, UK, The 
Netherlands, China, 
and Singapore 
Community-Level 
SES (poverty, 
homeownership, 
education, etc.) 
n/a 
MMSE, 3MSE, 
TICS, 
cognitive 
function tests 
11 studies found 
significant associations 
between community-
level SES and cognitive 
function 
Rusmaully, 
2017242 
Prospective 
Cohort 
(n = 7,499) 
Whitehall II Study 
(age: 45-69) 
Individual-Level 
SES (education 
and occupation) 
18.0 
years 
Global 
cognitive 
function test, 
dementia 
SES was not associated 
with cognitive decline 
or dementia 
Staff, 2016243 
Prospective 
Cohort 
(n = 478) 
Aberdeen Birth 
Cohort 
(age: 63-78) 
Individual-Level 
SES (education, 
parent and 
participant 
occupation) 
15.0 
years 
Cognitive 
function test 
(Digit Symbol 
Substitution) 
SES is not associated 
with decline in 
cognitive test score 
Dekhtyar, 
2015244 
Prospective 
Cohort 
(n = 7,574) 
Uppsala Birth 
Cohort 
Multigenerational 
Study 
(age: 41-55) 
Life Course 
Cognitive Reserve  
(education, school 
grades, 
occupational 
complexity) 
21.0 
years Dementia 
Higher graders in 
school and high 
occupational 
complexity were 
associated with reduced 
risk of dementia 
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Yaffe, 
2013245 
Prospective 
Cohort 
(n = 2,457) 
Health, Aging, and 
Body Composition 
Study 
(age: 70-79) 
Individual- Level 
SES (family 
income, financial 
inadequacy, 
education, 
literacy) 
12.0 
years Dementia 
SES was not associated 
with risk of dementia 
by race (Black/White), 
but SES may account 
for increased risk of 
dementia in Blacks 
Glymour, 
2008102 
Prospective 
Cohort 
(n = 11,427 and 
5% of US 
Census 1980 
sample) 
Health and 
Retirement Study 
and US Census 
1980 
(age: 66-33) 
Compulsory 
schooling law-
induced change in 
educational 
attainment (as 
instrumental 
variable) 
3.9 years 
MMSE, 
Cognitive 
function tests 
(Delayed Word 
Recall), TICS 
Education is 
statistically 
significantly associated 
with memory and 
mental status due to the 
causal effect of 
education 
Fischer, 
2009246 
Case-Control 
(n = 217) 
Patients from 
Toronto’s St. 
Michael’s Hospital 
Memory Disorders 
Clinic 
(age: 21-91) 
Individual and 
Neighborhood-
Level SES (annual 
income and 
neighborhood 
income quartiles) 
4.0 years Dementia 
Low annual income was 
significantly associated 
with dementia while 
low neighborhood 
income was not 
associated 
Marengoni, 
2011247 
Prospective 
Cohort 
(n = 1,012) 
Aging in the 
Chianti Area: 
InCHIANTI Study 
(age: 65+) 
Individual- Level 
SES (education, 
occupation, job 
stress, financial 
condition) 
3.0 years 
MMSE, 
Activities of 
Daily Living 
questionnaire 
Low education, manual 
occupation, and high 
job physical demands 
were significantly 
associated with incident 
cognitive impairment 
without dementia 
Russ, 2013248 
Meta-Analysis 
(n = 86,508; n 
studies = 11) 
Cross-sectional 
studies from Health 
Individual-Level 
SES (occupation, 
education) 
n/a Dementia-Related Death 
No association between 
social class and 
dementia, but an 
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Survey of England 
(age: 35-107) 
association between 
low education and 
dementia in women 
Melrose, 
2015249 
Prospective 
Cohort 
(n = 333) 
UC Davis Aging 
Diversity Cohort 
(age: 60+) 
Childhood 
Individual-Level 
SES 
(morphometric 
data, parents’ 
education, father’s 
occupation, 
siblings, etc.) 
4.0 years 
Cognitive 
function tests 
(Spanish and 
English 
Neuropsycholo
gical 
Assessment 
Scales) 
Low SES was 
associated with greater 
decline in SENAS score 
Marden, 
201755 
Prospective 
Cohort 
(n = 10,781) 
Health and 
Retirement Study 
(HRS) 
(age: 50+) 
Individual-Level 
Life Course SES 
(childhood, early 
adult, late-life) 
14.0 
years 
Cognitive 
function tests 
(Delayed word 
recall and 
Informant 
Questionnaire 
for Cognitive 
Decline) 
Stable high SES was 
associated with best 
memory function and 
slowest cognitive 
decline over 10 years 
Everson-
Rose, 
2003250 
Prospective 
Cohort 
(n = 4,398) 
Chicago Health and 
Aging Project 
(ages: 65+) 
Individual-Level 
Childhood SES 
(parent 
occupation, parent 
education, family 
financial status, 
etc.) 
 
MMSE and 
Cognitive 
function tests 
(Symbol Digit 
Modalities 
Test) 
Childhood SES was not 
statistically 
significantly associated 
with cognitive change 
Turrell, 
2002251 
Cross-sectional 
(n = 486) 
Kuopio Ischemic 
Heart Disease Risk 
Factor Study 
Life Course 
Individual-Level 
SES (education, 
n/a 
Cognitive 
function tests 
(Trail Making, 
Lower SES associated 
with worse performance 
on cognitive tests; 
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(ages: 58-64) income, 
socioeconomic 
trajectory) 
Selective 
Reminding, 
Verbal 
Fluency, 
Visual 
Reproduction, 
and MMSE) 
Upward mobility 
reduced risk of decline 
whereas downward 
mobility did not 
increase risk of decline 
Kim, 2017252 
Retrospective 
Cohort 
(n = 136,217) 
Seoul Dementia 
Management 
Project (SDMP) 
(ages: 60-90) 
Individual and 
Neighborhood-
Level SES  
(medical aid, 
education, 
income) 
3.0 years 
Cognitive 
impairment 
(defined by 
MMSE score) 
Low SES at the 
individual and 
neighborhood levels, 
low education, and 
history of stroke were 
independent risk factors 
for cognitive 
impairment 
Haan, 
2011129 
Prospective 
Cohort 
(n = 1,789) 
Sacramento Area 
Latino Study on 
Aging (SALSA) 
(ages: 60-101) 
Life Course 
Individual-Level 
SES 
(child and 
adulthood) 
9.0 years 
 
 
 
3MSE and 
Spanish 
English Verbal 
Learning Test 
(SEVLT) 
Participants with 
advantages life course 
SES trajectories were 
less likely to have 
cognitive decline; 
association stronger in 
first and second 
generation Mexican 
families 
Abbreviations: MMSE: Mini-mental State Exam; 3MSE: modified Mini-mental State Examination; TICS: Telephone Interview for 
Cognitive Status 
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Table A. 2. Relative risks (95% CI) of adjudicated dementia and MCI per pooled standard deviation increment in cumulative 
individual LC-SES and cumulative individual LC-SES with education removed, ARIC 1987-2013 
Cumulative Individual Life Course SES† 
 
White African American 
n total = 8,588 n total = 2,617 
n events = 1,257 n events = 389 
Model 1 RR 0.98 (0.92, 1.04) 
0.94 
(0.85, 1.04) 
Model 2 RR 0.97 (0.91, 1.03) 
0.91 
(0.82, 1.02) 
Cumulative Individual Life Course SES With Education Adjusted Separately ‡ 
 
White African American 
n total = 8,588 n total = 2,617 
n events = 1,257 n events = 389 
Model 1 RR 
LC-SES 0.90* (0.84, 0.96) 
0.88* 
(0.78, 1.00) 
Education   
Some High School or 
Less 
1 
(Ref) 
1 
(Ref) 
High School Graduate 1.32* (1.11, 1.57) 
1.03 
(0.82, 1.29) 
Some College or More 1.40* (1.15, 1.69) 
1.14 
(0.88, 1.47) 
Model 2 RR 
LC-SES 0.90* (0.84, 0.96) 
0.87* 
(0.76, 0.99) 
Education   
Some High School or 
Less 
1 
(Ref) 
1 
(Ref) 
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High School Graduate 1.31* (1.09, 1.56) 
0.98 
(0.78, 1.24) 
Some College or More 1.39* (1.14, 1.68) 
1.09 
(0.84, 1.41) 
*Statistically significant (p-value < 0.05) 
†Pooled standard deviation = 2.79 
‡Pooled standard deviation = 2.29 
Model 1: adjusted for age, sex, and ApoE4 status 
Model 2: adjusted for Model 1 + BMI, hypertension, diabetes, HDL cholesterol, total cholesterol, alcohol drinking status, tobacco 
smoking status 
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Table A. 3. Relative risks (95% CI) of dementia and MCI per standard deviation† increment of cumulative neighborhood LC-SES, 
ARIC 1987-2013 
 
White African American 
n total = 8,588 n total = 2,617 
n events = 1,257 n events = 389 
Model 1 RR 0.97 (0.94, 1.01) 
0.99 
(0.93, 1.05) 
Model 2 RR 0.97 (0.94, 1.01) 
0.98 
(0.92, 1.05) 
Abbreviation: HR: Hazard ratio; CI: Confidence interval 
†Standard deviation = 1 for whites and African Americans 
Model 1: adjusted for age, sex, ApoE4 status, and cumulative individual LC-SES 
Model 2: adjusted for Model 1 + BMI, hypertension, diabetes, HDL cholesterol, Total cholesterol, alcohol drinking status, tobacco 
smoking status 
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Thyroid Dysfunction (Chapter 6) 
Table A. 4. Literature review of the association between thyroid function and cognitive impairment 
Citation Study Design Population Exposure Mean Follow-up Outcome Results 
Beydoun, 
2015278 
Prospective 
Cohort 
(n = 2,630) 
Whites and Blacks 
in Baltimore, MD 
(age: 30-64) 
TSH, T4, FT4, 
T3 4.6 years 
Cognitive Test 
Scores 
Higher TSH associated 
with faster cognitive 
decline 
de Jong, 2009282 
Prospective 
Cohort 
(n = 665) 
 
Japanese-
American men 
(age: 71-93) 
FT4, T4 4.7 years 
Incident 
Dementia and 
brain autopsy 
in sub-sample 
(n = 143) 
Greater T4 and FT4 
(per SD) associated 
with 20% and 30% 
higher hazard of 
dementia; greater T4 
associated with higher 
number of plaques and 
tangles 
Chaker, 2016283 
Prospective 
Cohort 
(n = 9,446) 
 
Rotterdam Study 
(mean age: 65) 
TSH, FT4, 
TPO 8.0 years 
Incident 
Dementia and 
MRI 
Higher TSH, FT4 
associated with 
increased hazard of 
dementia, while TPO 
positivity had 
decreased hazard. 
Thyroid function not 
associated with 
vascular brain 
abnormalities. 
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Napthali, 
2014284 
Cross-sectional 
(n = 3,253) 
 
Australians in 
Hunter 
Community Study 
(age: 55-84) 
TPO n/a Cognitive Test Scores 
No association 
between TPO 
positivity and 
cognitive test score 
Pasqualetti, 
2015285 
Meta-Analysis 
(n = 13 studies) N/A 
Subclinical 
Hypothyroidis
m 
n/a 
Incident 
Dementia and 
Cognitive Test 
Scores 
Subclinical 
Hypothyroidism was 
not associated with 
cognitive decline and 
dementia 
Yeap, 2012286 
Prospective 
Cohort 
(n = 3,401) 
Australian Men 
(age: 70-89) FT4, TSH 5.9 years 
Dementia-
related ICD 
codes 
Higher levels of FT4 
was associated with 
dementia diagnosis, 
but TSH was not 
associated. 
Volpato, 2002287 
Prospective 
Cohort 
(n = 628) 
Women’s Health 
and Aging Study 
(age: <65) 
T4, TSH 3.0 years Cognitive Test Scores 
Higher levels of T4 
were associated with 
greater cognitive 
decline, but no 
association with TSH. 
Moon, 2014288 
Prospective 
Cohort 
(n = 313) 
Korean 
Longitudinal 
Study on Health 
and Aging 
(KLoSHA) 
(age: <65) 
T4, TSH 5.0 years Dementia and MCI 
Low TSH levels were 
associated with 
incident dementia and 
MCI, but T4 was not 
associated 
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Tan, 2008289 
Prospective 
Cohort 
(n = 1,864) 
The Framingham 
Study 
(mean age: 71) 
TSH 12.7 years Dementia 
Lowest and Highest 
TSH levels associated 
with dementia in 
women (not men). 
Abbreviations: SD: standard deviation 
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Table A. 5. Relative risks (95% CI) of adjudicated dementia and MCI by anti-TPO positivity status, ARIC 1990-2017  
 
Anti-TPO Negative 
≤ 34 IU/L 
Anti-TPO Positive 
>34 IU/L 
n total = 9,379 n total = 1,441 
n events = 1,817 n events = 280 
Model 1 RR 1  (ref) 
1.02 
(0.85, 1.22) 
Model 2 RR 1  (ref) 
1.00 
(0.84, 1.19) 
Model 3 RR 1  (ref) 
1.02 
(0.85, 1.21) 
Abbreviation: RR: Relative risk; CI: Confidence interval 
Model 1: age, sex, race-center, ApoE4, income, and education  
Model 2: Model 1 + BMI, smoking status, hypertension, diabetes, drinking status, HDL cholesterol, and total cholesterol 
Model 3: Model 2 + CVD and baseline thyroid medication 
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Table A. 6. Relative risks (95% CI) of adjudicated dementia and MCI by anti-TPO positivity status and etiology, ARIC 1990-2013  
 
Primary or Secondary Cerebrovascular Etiology Other Etiologies 
Anti-TPO Negative 
≤ 34 IU/L 
Anti-TPO Positive 
>34 IU/L 
Anti-TPO Negative 
≤ 34 IU/L 
Anti-TPO Positive 
>34 IU/L 
n total = 8,213 n total = 1,268 n total = 8,929 n total = 1,371 
n events = 450 n events = 70 n events = 1,166 n events = 173 
Model 1 RR 1  (ref) 
0.95 
(0.71, 1.28) 
1  
(ref) 
0.88 
(0.73, 1.05) 
Model 2 RR 1  (ref) 
0.93 
(0.69, 1.24) 
1  
(ref) 
0.88 
(0.73, 1.04) 
Model 3 RR 1  (ref) 
0.93 
(0.69, 1.27) 
1  
(ref) 
0.87 
(0.73, 1.04) 
Abbreviation: RR: Relative risk; CI: Confidence interval 
Model 1: age, sex, race-center, ApoE4, income, and education 
Model 2: Model 1 + BMI, smoking status, hypertension, diabetes, drinking status, HDL cholesterol, and total cholesterol. 
Model 3: Model 2 + CVD and baseline thyroid medication 
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Table A. 7. Relative risks (95% CI) of adjudicated dementia and MCI by clinical categories of thyroid dysfunction, ARIC 1990-2017 
 
Hypothyroidism Eu-thyroidism Hyperthyroidism Overt Subclinical Overt Subclinical 
TSH > 5.1 mIU/L; 
FT4 < 0.85 ng/dL 
TSH > 5.1 
mIU/L; 
FT4 = 
0.85 - 1.4 ng/dL 
TSH =  
0.56 - 5.1 mIU/L; 
FT4 = 
0.85 - 1.4 ng/dL 
TSH < 0.56 mIU/L; 
FT4 = 
0.85 - 1.4 ng/dL 
TSH < 0.56 
mIU/L; 
FT4 > 1.4 ng/dL 
n total = 233 n total = 508 n total = 9,518 n total = 369 n total = 192 
n events = 43 n events = 85 n events = 1,873 n events = 62 n events = 34  
Model 1 RR 1.36 (0.70, 2.62) 
1.04 
(0.72, 1.50) 
1 
 (Ref) 
1.04 
(0.67, 1.62) 
1.19 
(0.90, 1.56) 
Model 2 RR 1.24 (0.66, 2.34) 
0.98 
(0.68, 1.40) 
1  
(Ref) 
1.02 
(0.66, 1.58) 
1.14 
(0.87, 1.49) 
Model 3 RR 1.25 (0.65, 2.38) 
0.97 
(0.68, 1.39) 
1  
(Ref) 
1.04 
(0.67, 1.63) 
1.13 
(0.85, 1.49) 
Abbreviation: RR: Relative Risk; CI: Confidence interval 
*P-value < 0.05 
Model 1: age, sex, race-center, ApoE4, income, and education 
Model 2: Model 1 + BMI, smoking status, hypertension, diabetes, drinking status, HDL cholesterol, and total cholesterol. 
Model 3: Model 2 + CVD and baseline thyroid medication 
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Table A. 8. Relative risks (95% CI) of adjudicated dementia and MCI by categorical distribution of thyroid hormone level, ARIC 
1990-2017 (Aim 2) 
Thyroid Stimulating Hormone 
 
Lowest 5% 
≤ 0.55 mIU/L 
Middle 90% 
0.56 – 5.97 mIU/L 
Highest 5% 
≥ 5.97 mIU/L TSH per 6.40 mIU/L 
n total = 541 n total = 9,738 n total = 541 n total = 10,820 
 n events = 90 n events = 1,910 n events = 97 n events = 2,097 
Model 1 RR 0.88 (0.56, 1.38) 
1 
(ref) 
1.01 
(0.70, 1.45) 
0.98 
(0.94, 1.03) 
Model 2 RR 0.89 (0.57, 1.37) 
1 
(ref) 
1.01 
(0.71, 1.43) 
0.98 
(0.94, 1.03) 
Model 3 RR 0.89 (0.57, 1.37) 
1 
(ref) 
0.99 
(0.68, 1.45) 
0.98 
(0.94, 1.03) 
Free T4 
 
Lowest 5% 
≤ 0.89 ng/dL 
Middle 90% 
0.90 – 1.35 ng/dL 
Highest 5% 
≥ 1.36 ng/dL FT4 per 0.18 ng/dL 
n total = 544 n total = 9,697 n total = 579 n total = 10,820 
n events = 101 n events = 1,896 n events = 100 n events = 2,097 
Model 1 RR 1.42 (0.94, 2.15) 
1 
(ref) 
1.28* 
(1.03, 1.59) 
0.96 
(0.90, 1.02) 
Model 2 RR 1.33 (0.89, 1.99) 
1 
(ref) 
1.24* 
(1.00, 1.54) 
0.97 
(0.92, 1.04) 
Model 3 RR 1.33 (0.89, 1.97) 
1 
(ref) 
1.24 
(0.99, 1.54) 
0.98 
(0.92, 1.04) 
Abbreviation: RR: Relative risk; CI: Confidence interval 
*P-value < 0.05 
Model 1: age, sex, race-center, ApoE4, income, education, and TSH or FT4  
Model 2: Model 1 + BMI, smoking status, hypertension, diabetes, drinking status, HDL cholesterol, and total cholesterol. 
149 
 
Model 3: Model 2 + prevalent CVD and baseline thyroid medication use 
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Migraine (Chapter 7) 
Table A. 9. Literature review of the association between migraine and cognitive impairment 
Citation Study Design Population Exposure(s) Follow-up Time Outcome(s) Results 
Kalaydjian, 
2007319 
Prospective 
Cohort 
(n = 1448) 
Baltimore ECA 
study 
participants 
(mean age = 52) 
Self-report of  
migraine 
symptoms  
12.0 years 
MMSE and Rey 
Verbal Learning 
Test 
Those with 
migraine had 
significantly less 
decline in MMSE 
and verbal 
memory over 
follow-up 
Rist, 2012320 
Prospective 
Cohort 
(n = 6349) 
Women’s Health 
Study 
(mean age = 65) 
Self-report of 
migraine 
headaches 
3.4 years TICS and cognitive tests 
Women with 
migraine did not 
have  greater 
cognitive decline 
compared to 
women without 
migraine 
Rist, 2011321 
Prospective 
Cohort  
(n = 1170) 
EVA Study 
(mean age = 69) 
Self-report of 
migraine 
symptoms 
4.0-5.0 
years 
MMSE and 
cognitive tests 
There was no  
difference in 
cognitive decline 
between those 
with and without 
history of 
migraine  
Hagen, 2014322 
Prospective 
Cohort 
(n = 51,859) 
The HUNT 
Study (Norway) 
(age = 50-95) 
Self-report of 
migraine 
symptoms 
13.0 years 
Dementia registry 
from hospital 
records 
Experience of 
headache was 
associated with 
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2.3 (95% CI: 1.4, 
3.8)  and 2.0 
(95% CI: 1.1, 
3.5) increased 
hazard of VaD 
and mixed VaD 
and AD, 
respectively 
Abbreviations: MMSE: Mini-Mental State Exam; TICS: Telephone Interview for Cognitive Status 
 
